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ABSTRACT 
Background: Over the last twenty years the incidence of herpes zoster (HZ) infection, also 
known as shingles, has been increasing among adults for unknown reasons. The economic 
burden of HZ is currently estimated at over $1 billion per year in the United States (U.S.) and is 
expected to increase as the susceptible adult population ages. HZ is caused by a re-activation of 
the varicella zoster virus (VZV), chicken pox, and more than 95% of adults living today carry the 
virus with a lifetime risk of 1 in 3 for developing HZ. In 2006 the FDA approved a vaccine for 
the prevention of HZ in adults 60 years and older and in 2011 approval was expanded to include 
adults age 50-59 years. Since 2006 rates of adult immunization for HZ have been modest, as of 
2015 approximately two-thirds of the US population ≥ 60 are still unvaccinated and more than 
94% of those ages 50-59 have not been vaccinated. There is now accumulating evidence of a 
significantly elevated risk of ischemic stroke (IS) within the first 12 months following infection 
with HZ. Every 40 seconds someone in the U.S. suffers a stroke with an estimated 795,000 
strokes per year. In the U.S. stroke is a significant cause of disability with costs estimated at $33 
billion per year including cost of healthcare, medication, and lost productivity. As the population 
in the U.S ages, the risk of both HZ infection and stroke will increase significantly thus 
impacting mortality, morbidity, and healthcare costs. The CDC Advisory Committee for 
Immunization Practices (ACIP) currently recommends routine vaccination against HZ for adults 
≥ 60 but does not recommend vaccination for adults age 50-59 years and does not provided any 
guidance or recommendations for adults who may be at increased risk of stroke associated with 
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HZ infection. The current ACIP vaccination recommendations for HZ are predominately based 
on clinical trial efficacy data and cost-effectiveness analyses (CEAs) in adults ≥ 60. These prior 
analyses did not included costs associated with the recent evidence demonstrating increased risk 
of stroke up to one year following HZ infection. 
Aims: The objectives of this study were as follows; 1) To assess the cost-effectiveness of a 
targeted HZ vaccination strategy for adults age 50-59 years at increased cardiovascular (CV) risk 
in whom vaccination is approved but not recommended; 2) To develop a white paper directed at 
payers, providers, and policy makers translating the findings from the analysis into appropriate 
population health dissemination, implementation, and adoption priority recommendations.  
Methods: A decision analytic Markov Model (MM) was used to compare costs and outcomes 
between two vaccination strategies; usual-care (no current vaccine recommendation) and 
targeted vaccination in adults age 50-59 years with cardiovascular disease (CVD) in a 
hypothetical cohort of 100,000 adults age 50-59 years. The private payer perspective was used as 
it best represents this population of adults age 50-59 years who are predominately employed and 
covered under employer sponsored commercial insurance. The simulated cohort was assessed for 
incidence of IS within 12 months following HZ infection occurring within the fifth decade of 
life. Risk was assessed from the age at entry to the analysis, median age 55, up to age 60 using 
TreeAge Pro 2017 software. The cohort was then aged out to 100 years or death, whichever 
came first. Costs were calculated using 2016 U.S. dollars.  
Findings: As it relates to aim one, compared to usual-care targeting HZ vaccination in adults age 
50-59 years with prevalent CVD was cost-effective with an incremental cost-effectiveness ratio 
(ICER) of $55,517 per quality of life-year (QALY) gained which falls well below the standard 
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willingness-to-pay (WTP) threshold of $100,000 utilized in previous HZ CEAs (Le & Rothberg, 
2015, 2016; Pellissier, Brisson, & Levin, 2007). The incremental cost of vaccinating the target 
population using a benchmark vaccination rate of 60% was $30.59 per person compared to 
$12.98 in the usual-care group with ICERs of $55,517 and $55,470 respectively. Moreover, 
when comparing the cost of universal vaccination in the entire 50-59 year old cohort cost-
effectiveness was maintained with an incremental cost of $176.51 per person and an ICER of 
$55,523. Adopting the targeted strategy resulted in 162 fewer cases of HZ and 14 fewer strokes 
per 100,000 persons. Regarding aim two, following safety and efficacy, cost-effectiveness 
analysis are considered an essential metric in vaccine policy making and a substantial driver of 
vaccine adoption by policymakers, payers, and providers. Translating these favorable cost-
effectiveness findings to policymakers, payers, and providers is necessary to help close the 
adoption curve gap in order to facilitate and inform effective and timely implementation 
strategies for HZ vaccination in this targeted population.  
Conclusions: This study demonstrated that targeted HZ vaccination in patients age 50-59 years 
at increased CV risk is cost-effective and thus updating ACIP policy recommendations regarding 
vaccination in this population for whom the vaccine is currently FDA approved but not 
recommended should be considered. Furthermore, this study showed that universal vaccination 
in the general 50-59 year old population is cost-effective. Given the very limited data on cost-
effectiveness of HZ vaccination in adults age 50-59 years, which has resulted in a lack of 
recommendation for this population, and recent evidence of IS risk the results of this study 
demonstrating cost-effectiveness of a targeted HZ vaccination strategy directly support the 
National Adult Immunization Plan (NAIP) to improve adult immunization uptake by providing 
economic evaluations which can be used to inform policymakers, payers, and providers.  
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SECTION I: INTRODUCTION AND THEORETICAL FRAMEWORK 
Statement of Problem 
Aging baby-boomers are rapidly re-shaping the United States (U.S.) age demographic. 
The U.S. Census Bureau reports average life expectancy has increased to 79 years, resulting 
from reduction in mortality at older ages (United States Census Bureau, 2017). U.S. adults are 
living longer but older adults are more susceptible to diseases and are prone to greater risk of 
associated complications. Risk of preventable diseases and associated co-morbidities in adults 
will continue to grow as the aging population increases. Several vaccine-preventable diseases are 
increasing among U.S. adults while rates of adult vaccinations continue to remain low. 
 In 1999 the Centers for Disease Control and Prevention (CDC) declared vaccination as 
the greatest public health achievement of the 20th century (Centers for Disease Control and 
Prevention, 1999). Tremendous progress has been made in reducing vaccine-preventable 
diseases among children however today the true burden of illness (BOI) from vaccine-
preventable diseases is greatest among adults (Bridges et al., 2015). High rates of vaccine-
preventable diseases in adults increase costs of healthcare and create additional burdens on 
healthcare services and delivery. Adult immunization coverage continues to be far below 
Healthy People 2020 (HP 2020) goals despite evidence of the effectiveness and economic 
benefits of vaccination (Jacob, Chattopadhyay, Hopkins, Murphy Morgan, et al., 2016; Williams 
et al., 2016).  
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Prior to the implementation of the Affordable Care Act (ACA), disease burden data in the 
U.S. indicated that more than 50% of adult deaths where associated with preventable disease and 
approximately 95% of U.S. healthcare spending is for treatment of chronic illness, including 
many preventable diseases, compared to 5% budgeted for health promotion and prevention 
(Nash, David et al., 2011). In a recent economic analysis of four adult vaccine preventable 
diseases, (influenza, pneumococcal disease, herpes zoster, and pertussis) the estimated annual 
cost of treatment for adults 50 years and older was $26.5 billion (McLaughlin, McGinnis, Tan, 
Mercatante, & Fortuna, 2015). In 2016, Ozawa et al. estimated vaccine-preventable disease costs 
(individual and societal) directly attributable to low uptake of adult immunizations at $9 billion 
including direct costs and lost productivity (2016).  
The first comprehensive National Adult Immunization Plan (NAIP) was released in 2016 
with the goal of improving adult immunization rates through public health and population health 
approaches in alignment with the established HP 2020 objectives (U.S. Department of Health 
and Human Services National Vaccine Program Office, 2016a). The NAIP established four goals 
to improve vaccine adoption across the lifespan (see Figure 1). The first and primary goal of the 
plan is to strengthen the adult immunization infrastructure and a key objective in that effort is to  
“generate and disseminate evidence about the health and economic impact of adult 
immunization, including potential diseases averted and cost-effectiveness with the use of current 
vaccines” (U.S. Department of Health and Human Services Vaccine Program Office, 2016, 
p.16). Currently there are very limited data on the economic impact of adult immunizations, and 
the NAIP calls out the need for this information as a “critically important element of the plan” 
(U.S. Department of Health and Human Services National Vaccine Program Office, 2016a). 
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Figure 1: National Adult Immunization Plan Goals 2016 
(U.S. Department of Health and Human Services National Vaccine Program Office, 2016a) 
The Office of Disease Prevention and Health Promotion (ODPHP), a division of HHS, 
established the HP 2020 goals for immunization coverage and monitors progress annually based 
on results from the National Health Interview Survey (NHIS) conducted by the CDC. NHIS is an 
annualized household survey administered by the U.S. Census Bureau for CDC’s National 
Center for Health Statistics using in person interviews. Questions related to immunization status 
are addressed to one randomly selected adult within each household (Williams et al., 2016). 
NHIS collects data on the following adult vaccines; hepatitis A, hepatitis B, human 
papillomavirus (HPV), herpes zoster (HZ), pneumococcal, Td, and Tdap. HP 2020 has 
established goals to improve rates for the following specific adult immunizations; pneumococcal, 
herpes zoster, and hepatitis B for healthcare personnel (U.S. Department of Health and Human 
Services Office of Disease Prevention and Health Promotion, 2017). Surveillance data from the 
2015 NHIS concluded that adult vaccine coverage continues to remain low for most routinely 
recommended vaccines and many rates are still below the HP 2020 goals (Williams et al., 2017).    
HP 2020 recommendations serve as the national “standard benchmark” for evaluating progress in 
improving adult immunizations but the current measure only tracks progress on a sub-set of adult 
vaccinations. HP 2020 sets goals and provides clinical and community-level recommendations 
for interventions to improve rates(Jacob, Chattopadhyay, Hopkins, Murphy Morgan, et al., 
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2016), but there are no requirements for adherence to those recommendations (the federal 
government has no such jurisdiction), however they serve as a guideline for other entities and 
organizations to establish benchmarks which can be used to monitor and rate system or physician 
level performance outcomes toward improving immunization rates. 
In 1964, under the direction of the Department of Health and Human Services (HHS) the 
Advisory Committee on Immunization Practices (ACIP) was created (Walton, Orenstein, & 
Pickering, 2015) and for the last 50 years this body of experts has been responsible for 
establishing recommendations for vaccine use and monitoring their safety and effectiveness. The 
current ACIP recommended immunization schedule for adults 19 years and older includes 
routine vaccination recommendations for 13 vaccine-preventable diseases based on various age 
and risk criteria. Vaccination against influenza, tetanus, diphtheria and pertussis (Td/Tdap) are 
recommended for all persons 19 years and older (unless other risk factors preclude vaccination). 
HPV is routinely recommended for adult females up to age 26 and for adult males 19-21 years 
and for males up to age 26 with at risk conditions. HZ is routinely recommended for all adults 
over age 60, and two different pneumococcal vaccinations are recommended for all patients age 
65 and over with supplementary recommendations for certain at risk populations. Additionally, 
measles, mumps, rubella, and varicella are recommended for adults who lack evidence of 
immunity or prior vaccination. Meningococcal, hepatitis A, hepatitis B, and Haemophilus 
influenza B (Hib) are also recommended in special high risk populations (Centers for Disease 
Control and Prevention, 2017a) (Appendix A). 
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Herpes Zoster (HZ)  
Risk of Herpes Zoster (HZ) virus increases with age and while the epidemiology is not 
well understood, rates of HZ have been gradually increasing across all age groups over the last 
20 years (Kenneth E Schmader & Dworkin, 2017). HZ virus, also known as shingles, is caused 
by a reactivation of the varicella zoster virus (VZV), commonly known as chickenpox. After 
initial infection with chickenpox the virus becomes dormant in the dorsal root ganglia of the 
central nervous system. This latency allows for potential future reactivation of the virus as HZ 
virus which is thought to be mediated by immunosenescence as a byproduct of aging or reduced 
immunity either through infection or increased stress to the immune system. HZ is an 
inflammatory neurological infection affecting millions of people every year and is characterized 
by a painful blistering rash. HZ rash develops over 5 to 7 days and can be accompanied by 
prodromal pain and/or tingling sensations. The itching, burning rash appears unilaterally and 
does not ordinarily cross the spine or midline of the abdomen, typically affecting one to three 
dermatomes (Kenneth E Schmader & Dworkin, 2017).  
Approximately 95% of all people living today have been infected with VZV and an 
estimated 25-35% of those are at subsequent risk of reactivation of the virus as HZ (Warren-
Gash, Breuer, Warren-Gash, & Breuer, 2017). After age 50 the risk of HZ infection increases. 
The overall incidence of HZ in the United States is approximately 4 cases per 1,000 annually and 
in people 60 years and older the rate is about 10 cases per 1,000 annually (Centers for Disease 
Control and Prevention, 2016a). Each year in the U.S. HZ affects approximately 1 million people 
and causes an estimated 96 virus-related deaths. Lifetime risk of HZ in the United States is 
approximately 1 in 3 and while most people will experience it only once, it is possible to have re-
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activation two or three times over a lifetime after initial infection with chickenpox with long-
term studies showing a 5-6% risk of recurrence (Kawai, Gebremeskel, & Acosta, 2014). Several 
studies report significantly higher incidence of HZ in adult women across all age groups 
(Johnson et al., 2015; Sundström et al., 2015), thus female gender is considered a risk factor for 
HZ (de Boer, Wilschut, & Postma, 2014). One in 4 people with herpes zoster are hospitalized 
due to complications which can range from mild to severe depending on the patient’s underlying 
immune status and other health risks (Centers for Disease Control and Prevention, 2016c). VZV 
is the only known virus with the capacity to produce pathologic vascular changes associated with 
stroke through infection of the cerebral arteries (Nagel & Gilden, 2015). HZ is the single most 
common infection of the nervous system in the U.S. (Warren-Gash & Breuer, 2017).  
The most common side effect of HZ infection is post herpetic neuralgia (PHN), which 
occurs in 10-18% of patients and is defined as prolonged pain at the site of the rash lasting at 
least 90 days following fading of the rash. PHN can persist for many months to years and can be 
debilitating. A potentially serious complication of HZ is herpes zoster opthamalmicus (HZO), 
which occurs when the virus infects the ophthalmic region of the trigeminal nerve 
(approximately 15% of patients) and can cause chronic complications, including pain and 
possible loss of vision (Centers for Disease Control and Prevention, 2016a). Secondary 
complications such as bacterial infections and transmission of the virus to other susceptible 
individuals can occur (although this is rare and transmission would cause the primary VZV, 
chickenpox, not HZ) (Kenneth E Schmader & Dworkin, 2017).  
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Herpes Zoster Vaccine 
In June 2006 the U.S. Food and Drug Administration (FDA) approved a live attenuated 
vaccine for HZ (Zostavax®; Merck) for the one-time vaccination of immunocompetent adults     
≥ 60 years for the prevention of HZ and expanded the approval to immunocompetent patients 
age 50-59 years in 2011(Centers for Disease Control and Prevention, 2011). The ACIP 
recommends universal HZ vaccination of all adults ≥ 60 but does not currently recommend HZ 
vaccination for adults age 50-59 years, despite FDA approval for this population. The ACIP has 
cited concerns around duration of vaccine efficacy and poor cost-effectiveness of the vaccine as 
the main reasons for not making a recommendation for persons 50-59 years of age (Centers for 
Disease Control and Prevention, 2016c). Although risk of HZ is greater in adults over age 60 
there is still significant disease in younger patients. In 2015, Johnson and colleagues estimated 
incidence of HZ in adults age 50-59 at 6.74 per 1,000 person-years which represents an increase 
over previous estimates (Johnson et al., 2015). More than ten years after vaccine approval and 
ACIP universal recommendation for adults ≥60, rates of HZ vaccination remain low and 
continue to show limited improvement year over year. In 2015 HZ vaccination uptake in the 
universally recommended adult population of ≥ 60 finally achieved the modestly set HP 2020 
goal of 30%, which is the lowest target rate for all recommended adult immunizations (see Table 
1). The most recent data on HZ vaccination rates for the ACIP universal age based population 
reported coverage of 30.6% for adults ≥ 60 years and 34.2% for those ≥ 65 years, with the lowest 
rates in the 60-64 age group at 21.7% (Williams et al., 2017). The lower rate in adults 60-64 is of 
interest because that age group is made up of many adults who are still active in the workforce 
and are predominantly covered under commercial insurance compared to those over 65 where 
the vaccine is considered a pharmacy benefit under Medicare.  
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Table 1: Healthy People 2020 Adult Vaccination, 2013 Coverage and 2020 Targets  
 
 
 
(Adapted from "National Adult Immunization Plan" Department of Health and Human Services National Vaccine 
Program Office, 2016). 
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Significant racial and ethnic disparities for HZ vaccination persists with immunization 
coverage being highest among whites for all age groups (Williams et al., 2017). Data on rates of 
HZ immunization for those under age 60 are less reliable because the ACIP does not recommend 
the vaccine for this age group. The most recent data collected by the CDC using the 2014 
Behavior Risk Factor Surveillance System (BRFSS) reported coverage of 5.9% among adults 
age 50-59 years and suggested that the lower coverage compared to other groups may be 
partially due to lack of an official ACIP  recommendation in this population (PJ. Lu, O 
’Halloran, Williams, & Harpaz, 2017). A 2013 estimate of HZ vaccination coverage among 
insured adults over age 50 showed approximately 1.7% of adults age 50-59 had been vaccinated 
(D. Zhang, Johnson, Newransky, & Acosta, 2017) and a study of Kaiser Permanente patients 
conducted between 2007 and 2014 found only 4.5% of patients age 50-59 had been vaccinated 
(Baxter et al., 2017). As stated previously, incidence of HZ has been increasing over the last 20 
years for unknown reasons across all age groups. A 2017 population based burden of disease 
analysis from Canada reported “a significant increase in the incidence of HZ, independent of 
demographic shifts in the population, was found to begin in 2009/10”, and was also found to be 
associated with increased medical cost per episode and total annual costs (Friesen, Chateau, Falk, 
Alessi-Severini, & Bugden, 2017). 
Zostavax® was initially studied in adults ≥ 60 in the Shingles Prevention Study (SPS) 
and demonstrated a 51% reduced risk of HZ infection in that population. Protection against 
infection was greatest in patients 60-69 years of age with 64% efficacy, then declined in patients 
70-79 years of age to 41%, and in patients ≥ 80 vaccine efficacy was 18% (Oxman et al., 2005). 
Efficacy of Zostavax® was studied in patients 50-59 years of age in the Zostavax Efficacy and 
Safety Trial (ZEST) which demonstrated reduced risk of developing HZ of 69.8% (Kenneth E 
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Schmader et al., 2012). The Short-Term Persistence Sub-study (STPS) and the Long-Term 
Persistence Sub-study (LTPS), both conducted in patients ≥ 60, have shown the vaccine is 
effective in reducing incidence of HZ, PHN, and overall BOI up to 10 years post-vaccination 
(Morrison et al., 2015; K. E. Schmader et al., 2012). Post licensure studies assessing the 
durability of the vaccine to prevent HZ infection alone (not in combination with PHN and/or 
BOI) have shown declining protection for Zostavax® with evidence of vaccine efficacy through 
5 years after vaccination and uncertain efficacy beyond 5 years (Morrison et al., 2015; K. E. 
Schmader et al., 2012). A Kaiser Permanente cohort study conducted between 2007 and 2014 
included patients 50 and over and reported higher vaccine efficacy during the first year after 
vaccination, but demonstrated decline in the second year and ongoing gradual decrease in 
subsequent years, reporting average efficacy of 59.5% three years after initial vaccination 
(Baxter et al., 2017). Limitations on long-term follow up efficacy and duration of protection of 
Zostavax® in adults age 50-59 years is largely due to the shorter time horizon since the vaccine 
was approved for this population in 2011 and the subsequent limited uptake. 
Stroke Risk and Herpes Zoster  
Mounting evidence of an association between HZ infection and stroke has been reported 
in the medical literature and is thought to be mediated through inflammatory vasculopathy 
resulting from VZV viral arterial infection (Nagel & Gilden, 2014, 2015; Powell, Patel, Franco-
Paredes, & Lopez, 2015). The first studies to investigate the association between VZV and 
vascular remodeling began in 1959 and more recent epidemiologic studies from three countries 
in Asia and Europe have shown a 30% increased risk of stroke within one year of HZ infection 
establishing HZ as a significant risk factor for stroke (Gilden, Nagel, Cohrs, & Mahalingam, 
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2013). Nagel and Gilden suggest that the frequency of stroke after HZ is likely underestimated 
because VZV can reactivate without evidence of rash, therefore there may not be a HZ diagnosis 
(2015). VZV related vasculopathy and stroke have been reported in children but are much less 
common likely due to high rates of  pediatric varicella vaccination (Nagel, Jones, & Wyborny, 
2017). 
An increase in the abundance of literature demonstrating HZ as a risk factor for stroke 
began appearing in 2009 predominately from cohort and case-controlled studies conducted in 
Taiwan, Demark, Sweden, United Kingdom (U.K.) and the U.S., each providing supporting 
evidence of a pronounced association between HZ and transient ischemic attack (TIA), 
myocardial infarction (MI), and stroke within one year of infection with HZ (Breuer, Pacou, 
Gauthier, & Brown, 2014; Kang, Ho, Chen, & Lin, 2009a; Langan, Minassian, Smeeth, & 
Thomas, 2014a; Minassian et al., 2015; Nagel, Jones, & Wyborny, 2017; Sreenivasan et al., n.d., 
2013; Sundström et al., 2015; Yawn, Wollan, Nagel, & Gilden, 2016). Five meta-analyses 
published within the last year have reported associated relative risk (RR) of stroke within the 
first month after HZ with values ranging from 1.55 to 1.94, which then slowly decline, values of 
RR out to 12 months post virus range from 1.17 to 1.20. These studies assessed independent risk 
of transient ischemic attack (TIA), ischemic stroke (IS), hemorrhagic stroke (HS), and 
myocardial infarctions (MI) and found consistent statistical significance associated with HZ 
infection and IS further confirming the association reported in the individual studies. RR was 
highest in the time period just after HZ infection with risk gradually declining over time showing 
statistical significance out to one year after infection (Lian, Zhu, Tang, Yang, & Duan, 2017; Liu 
et al., 2016; Marra, Ruckenstein, & Richardson, 2017a; Yang et al., 2017; Zhang, Yanting; Luo, 
Ganfeng;Huan, Yuanwei; Yu, Qiuyan; Wang, Li; Li, 2017a).  
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Asserting that prior studies had not effectively accounted for confounding factors in 2017 
Kim et al. conducted a propensity score-matched analysis using a Korean population database of 
over 570,000 people and reported confirmatory results from the previous published analyses. 
When adjusting for confounding this study reported a RR of stroke associated with HZ of 1.39 
(95% CI 1.05-1.84) in adults 51-60; the study included additional age and CVD specific analyses 
(M.C. Kim et al., 2017). Prevention of HZ is possible through vaccination, suggesting that 
vaccinating patients at increased risk of CVD could reduce risk of stroke associated with HZ 
infection (Zhang, Yanting; Luo, Ganfeng;Huan, Yuanwei; Yu, Qiuyan; Wang, Li; Li, 2017b).  
Stroke Risk 
Although the incidence of stroke increases with age, it can strike at any time. In 2009, 
34% of people hospitalized for stroke were under age 65 (Centers for Disease Control and 
Prevention, 2016d). There are an estimated 795,000 strokes per year in the U.S. and more than 
75% of those are primary strokes. Stroke is a significant cause of disability with costs estimated 
at $33 billion per year including cost of healthcare, medication, and lost productivity (Centers for 
Disease Control and Prevention, 2016d). A stroke occurs when the blood flow to the brain is 
interrupted. An ischemic stroke (IS) results from an obstruction such a clot in a blood vessel 
leading to the brain while a hemorrhagic stroke (HS) results from a ruptured or broken blood 
vessel in the brain (Centers for Disease Control and Prevention, 2016). IS represents 87% of all 
strokes in the U.S. with HS comprising the remaining 13% (Benjamin et al., 2017).  
Stroke represents a significant economic and health care delivery burden - every four 
minutes someone in the U.S. dies from stroke (Centers for Disease Control and Prevention, 
2016d). In 2014 the CDC Division for Heart Disease and Stroke Prevention reported that the 
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American Heart Association (AHA) predicts direct medical costs from stroke will increase 238% 
between 2010 to 2030, which represents a higher predicted increase than estimated for any other 
CVD (including hypertension, coronary artery disease, or heart failure) (Wang et al., 2014). A 
significant proportion of strokes occur in adults under age 65 and estimates suggest that by 2050 
about half of stroke-related costs, including treatment, rehabilitation, and lost productivity, will 
be incurred in this age population (Wang et al., 2014). A recent U.S. based analysis of real world 
third-party payer and patient out of pocket costs, including acute hospitalization and long-term 
follow up, within one year after IS ranged from $41,566 for patients with a disability at discharge 
to $26,687 for patients discharged without disability (Mu et al., 2017). Wang et al. suggest that 
understanding stroke risk in patients under age 65 will not only aid in development of 
appropriate intervention and prevention programs but subsequently reduce economic and societal 
burden associated with the anticipated increase in stroke incidence (Wang et al., 2014). 
Herpes Zoster Vaccine Recommendations  
The current ACIP universal age-based HZ vaccination recommendation for adults age     
≥ 60 years does not address risk factors for patient sub-populations such as patients at increased 
CV risk. Universal vaccination is considered optimal from a public health approach, specifically 
as it relates to the benefits of herd immunity, and many adult immunizations such as 
pneumococcal and influenza have additional recommendations for patients with certain medical 
conditions (risk-based) in addition to universal (age-based) recommendations (P Bonanni, Sacco, 
Donato, & Capei, 2014). Cost-effectiveness analyses (CEAs) lean toward supporting targeted 
vaccine programs aimed at persons with the highest risk of disease because they yield the 
greatest return based on disease averted calculated on cost per dose administered. Universal 
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strategies in conjunction with targeted strategies have been shown to be most effective in 
reducing disease (Balicer et al., 2014; Hardt et al., 2016). Unlike influenza and pneumococcal 
viruses, HZ is non-communicable therefore traditional herd protection afforded by universal 
vaccination does not convey the same public health benefit (Centers for Disease Control and 
Prevention, 2016b). Prior to the emerging literature elucidating risk of stroke after HZ infection 
there were no evidence based risk factors on which to establish a targeted strategy for HZ 
vaccination leaving universal approach as the most appropriate option which was heavily reliant 
on cost-effectiveness data. 
The economic burden of HZ is significant and has increased over time and will continue 
to increase as the population ages (Donatella Panatto et al., 2015). The direct cost burden from 
drugs, physician visits, hospitalization, and diagnostics associated with HZ are estimated at over 
$1 billion per year in the U.S. (Johnson et al., 2016b). Much of the published data on HZ cost-
effectiveness are based on patients ≥ 60 and have demonstrated favorable results supporting the 
ACIP recommendation in this age group (Kawai, Preaud, Baron-Papillon, Largeron, & Acosta, 
2014). Following the 2011 FDA approval of Zostavax® in persons age 50-59 years the ACIP 
declined to recommend the vaccine for this age group due to concerns about supply shortages 
and limited data on long-term protection in this population, a footnote was made that providers 
might chose to vaccinate patients who would have “particularly poor anticipated tolerance of HZ 
or post herpetic neuralgia symptoms” (Centers for Disease Control and Prevention, 2011). In a 
2014 follow up review of HZ recommendations for persons age 50-59 years the ACIP again 
declined to expand the recommendation for this population based on unfavorable results of an 
unpublished CEA conducted by the CDC (Hales, C.M., Harpaz, R., Ortega-Sanchez, I., Bialek, 
2014; Le & Rothberg, 2015). Under the Affordable Care Act (ACA) only ACIP recommended 
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vaccines are covered with no out of pocket costs, and because the vaccine is not recommended 
for patients age 50-59 years, those who choose to receive HZ vaccination may not receive this 
coverage benefit. 
The ACIP has declined to recommend HZ vaccination for adults age 50-59 based on 
limited data on durability of protection and lack of cost-effectiveness however these decisions 
did not account for the recent evidence of associated stroke risk and therefore have not 
considered a targeted risk based approach to vaccine recommendations in this population. HZ in 
persons age 50-59 years represents a significant economic and population health burden 
including direct costs and lost productivity since most adults in this age range are still active in 
the workforce (Johnson et al., 2015). Both ZEST and SPS demonstrated that efficacy of 
Zostavax® in preventing HZ infection is greatest in younger age groups. While overall rates of 
HZ infection are lower in adults age 50-59 years, a recent study suggests that approximately 25% 
of HZ cases occurred in the 50-59 year age group and those also incurred higher incremental 
costs for treatment (Johnson et al., 2016b). The total direct medical costs associated with stroke 
are projected to almost triple between 2012 and 2030 from $71.6 billion to $184.1 billion. 
Finding cost-effective interventions to reduce stroke risk associated with HZ could provide 
significant public health benefits in population health disease burden reduction while also having 
a significant potential impact on the economic burdens associated with both HZ and stroke.  
CEAs for HZ are highly dependent on the age of vaccination and presumptions about 
duration of protection (durability) of the vaccine (Kawai, Preaud, et al., 2014). The ACIP 
recommendations for use of Zostavax® have heavily relied on cost-effectiveness results from 
patient’s ≥ 60. Information on duration of protection and cost-effectiveness of HZ vaccination in 
persons age 50-59 years are limited. While efficacy of the vaccine in adults age 50-59 years from 
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ZEST is estimated at nearly 70%, duration of vaccine protection was considered short term at 1.5 
years (Schmader et al., 2012). Using a 2007 published Markov decision model comparing the 
cost-effectiveness of HZ vaccine to no vaccine in adults ≥ 60 years (Rothberg, Virapongse, & 
Smith, 2007), Le and Rothberg adapted the model to assess the cost-effectiveness of HZ vaccine 
in persons aged ≥ 50 years (2015). Without long term vaccine efficacy data available for persons 
age 50-59 years, the Le and Rothberg model adjusted for estimated efficacy in this population 
using the previously published ZEST and the LTPS (Morrison et al., 2015; Schmader et al., 
2012). Although this analysis took into consideration the potentially higher vaccine efficacy in 
the 50-59 year old population the study concluded that vaccination did not meet generally 
accepted standards for cost-effectiveness, supporting the standing decision of ACIP not to 
recommend use in this population (Le & Rothberg, 2015).  
           HZ is a risk factor for stroke. Recent evidence signals significantly elevated short term risk 
of stroke following infection with HZ persisting for up to twelve months. Stroke is the fifth 
leading cause of death in the U.S. - every 40 seconds someone experiences a stroke and every 
four minutes one of them will die (Centers for Disease Control and Prevention, 2016d). To date 
there have been no studies to assess the cost-effectiveness of a targeted HZ vaccination strategy, 
either alone or in combination with a universal approach, in adults age 50-59 years who are at 
increased CV risk.  
Adult immunization rates continue to remain low for most recommended vaccines 
specifically in contrast to other preventive service interventions. There has been much research 
and discussion about factors associated with low adult immunization uptake. An environmental 
scan employed in the development of the NAIP identified relevant barriers associated with adult 
immunizations and found the following as the most critical; lack of public awareness of 
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recommended vaccines and risk associated with vaccine preventable diseases, lack of strong 
provider recommendations, and limited use of evidence-based strategies (Department of Health 
& Services National Vaccine Program Office, 2016). In response, goals of the plan have been 
developed around addressing these specific barriers. Information and awareness of increased risk 
of stroke associated with HZ infection has not been widely or formally communicated to payers, 
patients, or policy makers. The evidence supporting this association has only just begun 
appearing in the medical literature and the gap between evidence based data appearing in the 
medical literature and time to clinical adoption is estimated at 17 years (Balas & Boren, 2000). 
Effective and timely implementation of findings from clinical research is critical to improving 
population health outcomes and reducing the adoption curve for evidence based practices 
(Evans, Snooks, Howson, & Davies, 2013). Clinical and health services research has shown that 
failure to translate research into practice and policy is an ongoing public health challenge  
(Grimshaw, Eccles, Lavis, Hill, & Squires, 2012). 
Study Purpose 
 Given that a large proportion of strokes occur in adults under age 65 and it is projected 
that the cost of treating stroke in this population will account for half of all stroke related 
expenditures by 2050 (Wang et al., 2014), studying the potential benefit of a targeted HZ 
vaccination approach for adults age 50-59 years who are already at some increased risk of stroke 
could provide a significant contribution to identifying cost-effective interventions to reduce 
stroke risk in this population. The 2017 AHA Heart Disease and Stroke Statistics update reports 
the prevalence of CVD in adults ≥ 20 years at 36.6% and projects that by 2030, 43.9% of the 
U.S. population will have some form of CVD (Benjamin et al., 2017). These data only represent 
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those who have active diagnosed cardiovascular diseases (atherosclerosis, chronic heart disease 
(CHD), heart failure (HF), prior MI or stroke, etc.) and does not begin to account for the millions 
more Americans with one or more risk factors for CVD. The Framingham Risk Scoring criteria 
estimates risk of developing CVD or some component of CVD (such as coronary heart disease, 
stroke, peripheral vascular disease, or heart failure) over a fixed time period by assessing risk 
factors such as sex, age, systolic blood pressure, total cholesterol, high-density lipoprotein 
cholesterol, smoking behavior, and diabetes status and uses these “risk scores” to recommend 
interventions (D ’Agostino, Pencina, Massaro, & Coady, 2013). These risk criteria could serve as 
the foundation of a targeted recommendation for HZ vaccination as a potential primary 
prevention for stroke in patients with increased CV risk factors or active disease, specifically in 
the 50-59 year old population for whom the vaccine is FDA approved but not currently 
recommended by the ACIP. 
In an effort to support the NAIP goal of generating and disseminating evidence of cost-
effectiveness with the use of current vaccines, the purpose of this study was to evaluate targeted 
HZ vaccination strategies in adults 50-59 years of age who are at increased CV risk. This study 
aimed to: 
 1. Develop an analytic model to assess the cost-effectiveness of a targeted vaccination 
intervention in an immunocompetent population of adults age 50-59 years, comparing two 
treatment strategies; usual-care vaccination, no current ACIP recommendation for adults age   
50-59, versus achieving a 60% vaccination rate among a targeted population of adults at 
increased CV risk. This assessment considered the cost-effectiveness of HZ vaccination in 
reducing the risk of IS within one year of HZ infection. HZ outcomes were based on reduction of 
infection only and not associated morbidities of PHN and BOI. 
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2. Translate cost-effectiveness outcomes and related incremental cost-effectiveness 
ratio’s (ICERs) for a target audience of three key healthcare stakeholder groups; payers, 
providers, and policymakers for the propose of dissemination and implementation of 
recommendations for reducing stroke associated with HZ and improving access and uptake of 
HZ vaccination in adults age 50-59 years.     
Review of Theory and Frameworks 
Endeavoring to advance evidence of the economic benefits of adult immunization is a 
cornerstone of the NAIP. Multiple CEAs have been conducting since the introduction of the 
vaccine for the prevention of HZ. The SPS was the primary randomized controlled clinical trial 
(RCT) for Zostavax® and was conducted in a cohort of immunocompetent adults over age ≥ 60 
thus establishing a foundation for the predominance of cost-effectiveness analyses using this 
same population. A 2014 review of HZ CEAs by de Boer, Wilschut, and Postma identified the 
majority of  these studies as having applied “traditional” decision analytic models (Cohort 
Models and Markov Models ) and noted that the perspective most often used was that of the 
healthcare payer followed by the societal perspective (de Boer et al., 2014).  
Cost-Effectiveness Analysis 
Facilitated by ACA, healthcare delivery has been moving from a volume based fee-for-
service (FFS) approach to a value based payment system accelerating significant changes in 
health care delivery. This shift is linked to quality improvement metrics and measures which 
push financial risk to the payer and provider level. Quality measures tied to performance and 
increased risk sharing on the part of the payers and providers is imposing greater focus on 
evidence-based outcomes. Healthcare decision making is now about prioritizing health 
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interventions in an environment of scarce and/or limited resources while assuring adherence and 
successful performance to meet quality metrics. Healthcare delivery systems are adopting 
Population Health Management (PHM) approaches (looking at patient populations tied to 
outcomes) to more effectively meet both performance and outcome measures. CEAs are an 
important influencer of informed outcome-driven healthcare decision making. 
Cost-effectiveness can be defined as “the additional cost required per additional unit of 
health benefit produced as compared with the next most effective alternative” (J. J. Kim, 2011). 
As a form of economic evaluation CEAs are designed specifically to examine the difference in 
magnitude associated with the costs of healthcare interventions or treatments and are typically 
expressed as quality-adjusted life year gained (QALY), defined as costs in dollars and health 
benefits in units of health and incremental cost-effectiveness ratio’s (ICERs), which represent the 
difference in cost between the interventions being considered divided by the difference in their 
effectiveness (Drummond, Sculpher, Torrance, O’Brien, & Stoddart, 2005; Owens, 1998). In the 
changing healthcare marketplace there is increasing focus on cost-containment and its 
relationship to value, as a result CEAs play a significant role in aligning cost expenditures to 
anticipated outcomes and are a critical consideration for healthcare decision making among 
policy makers and payers (Bang & Zhao, 2014). 
Population Health Framework 
 The distinction between population health and public health is still not well appreciated 
even in academic settings. The most simplistic distinction between population health and public 
health is that population health refers to specific measurable health outcomes and public health 
defines the approaches used to provide health to the nation’s population. For the purpose of this 
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analysis the perspective was based on a population health point of view keeping in mind that the 
measures we select to evaluate must address the health determinants which influence the 
outcomes we seek to impact. Kindig and Stoddard’s Population Health Framework model 
diagrams the inter-relationships between health outcomes, patterns of health determinants, and 
policies and interventions at the individual and society levels (2003). This framework provided 
the foundational approach for the evaluation of appropriate interventions and sustainable 
intervention strategies used to translate the research findings into recommendations for the key 
stakeholders groups. 
Kindig and Stoddard contend that a population health approach requires consideration of 
the specific allocation of resources employed to link determinants to outcomes, specifically the 
ability to evaluate cost-effectiveness across various intervention strategies (2003). Population 
health is achieved through the interaction and cooperation of multiple stakeholders such as 
payers, providers, and policymakers with a focus on effective knowledge transfer and 
dissemination among and between the various stakeholders (D. Kindig & Stoddart, 2003). The 
importance of the interplay between multiple stakeholders requires analysis of how the 
sequences of interventions rely on one another and if there is a necessary hierarchy to their 
adoption.  
The primary objective of this study was to determine if a HZ vaccine intervention was 
cost-effective relative to the cost of treating stroke within the year following infection with HZ. 
Applying the population health framework, reduction of HZ and HZ related stroke are the 
outcomes to be measured and the translation of these findings is necessary to identify and 
address health determinants associated with vaccine adoption, from all three stakeholders 
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perspectives, including cost, access, risk perception, and benefits. In addition, analysis of   
potential policies and interventions at the individual and societal levels which can positively 
influence those determinants must also be evaluated and translated into recommendations. 
 Implementation Science 
Implementation science is defined as: “research relevant to the scientific study of 
methods to promote the uptake of research findings into routine healthcare in clinical, 
organizational or policy contexts” (Eccles & Mittman, 2006). While considered a nascent field 
by some measures, the fundamental constructs of implementation science have been known for 
decades. The literature supports the consensus of the failure for timely and efficient translation of 
medical research findings into clinical practice and public policy (Haines, Kuruvilla, & Borchert, 
2004).  In 2000, Balas and Boren first reported that it takes an average of 17 years for health 
research to reach clinical practice, compared to newer technological innovations which take an 
average of four to six years (ex. iPhone/iPad) (2000).  
Improving adult immunization rates will require efficient and sustainable intervention 
strategies. Adult immunization efforts lack the structure of routine well care visits, provider 
awareness, standardized policy, insurance and federal program cost coverage, and quality 
measures which are well established for pediatric patients. Efforts to improve rates in this 
population will require a multi-disciplinary approach. Applying a scientific approach to 
implementation is essential to bridging the gap between knowledge and practice. 
There is a core foundation for implementation science under the umbrella of population 
health. Implementation science is interdisciplinary in nature, applying theories and knowledge 
from other domains such as; economics, behavior science, clinical research, public policy, 
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quality and performance improvement, social sciences, and marketing. As shown in Figure 2, 
successful and sustainable implementation approaches require multilevel, sequential intervention 
strategies that are interdependent (Fixsen, Naoom, Blase, Friedman, & Wallace, 2005). 
Translating evidenced-based research findings into practice requires a comprehensive 
understanding of the target population, the interventions being considered, and the structural 
capacity, internal and external influencers, and barriers unique to each stakeholder. 
 
Figure 2: Multilevel Influences on Successful Implementation. From “Implementation Research: 
A Synthesis of the Literature”, by D. L. Fixsen, S.F. Blasé, R.M. Friedman and F. Wallace, 2005, 
National Implementation Research Network, p. 59. Copyright 2005 by Louis de la Parte Florida 
Mental Health Institute Publication #231 Tampa, Florida. Used with permission. 
Conceptual Model 
 A simulated cohort of 100,000 immunocompetent adults age 50-59 years was developed 
in TreeAge Pro 2017 software employing a decision tree analytic and Markov model (MM) 
using two vaccination strategies to assess the cost-effectiveness of targeted HZ vaccination to 
reduce stroke risk in adults with increased CV risk, compared to usual-care (see Figure 3). For 
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purposes of the model, CV risk was established using current AHA CVD prevalence data as a 
proxy, which only captures those with active disease, not those who are “at-risk”. CV risk factors 
as established by the Framingham Risk Scoring criteria include; hypertension, hyperlipidemia, 
diabetes, age, and smoking history, whereas CVD represents those with active disease 
(D’Agostino et al., 2008; D ’Agostino et al., 2013).  
The model compared usual care, no current ACIP recommendation for HZ vaccination in adults 
age 50-59 years, to a HZ targeted vaccination approach in adults age 50-59 years who are at 
increased CV risk with the goal of achieving a 60% vaccination rate in the targeted population. A 
Monte Carlo (MC) simulation of the hypothetical cohort was performed using probabilistic and 
deterministic parameters to estimate costs and ICERs for each treatment strategy. Costs and 
ICERs for each of the possible intervention strategies were then ranked by ICER and compared 
to standardized willingness-to-pay (WTP) thresholds to determine which interventions produce 
the greatest value.  
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Figure 3: Example of Decision Tree  
 
 
Model Parameters 
Many of the parameters in this study were derived from a previously published CEA of 
HZ in adults age 50-59 years by Le & Rothberg permitting assessment of concordance of results 
(Le & Rothberg, 2015). A review of recent literature and data sources was conducted to update 
parameters that may have changed since 2015 in an effort to select the best and most recent 
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inputs for the model. Other probabilistic and base-case parameters were pulled from the literature 
and prior publications (Le & Rothberg, 2015; Pandya, Sy, Cho, Weinstein, & Gaziano, 2015). 
HZ incidence rates and healthcare utilization costs were based on the most recent data in 
immunocompetent adults in the U.S. (Johnson et al., 2015, 2016b). CVD prevalence and 
associated costs were drawn from the 2017 Heart Disease and Stroke Statistics (Benjamin et al., 
2017) and direct IS costs from a payer perspective was derived from a real-world cost analysis 
published in 2017 (Mu et al., 2017). Background age and sex specific mortality rates were 
obtained using U.S. life tables for all-cause mortality (Centers for Disease Control and 
Prevention, 2017c).  
Risk of stroke associated with HZ infection was drawn from a 2015 self-controlled case 
series (SCCS) analysis of a U.S. Medicare population of adults ≥ 65 years with a HZ diagnosis 
and IS within defined time periods using data gathered between January 2006 and December 
2011 (Minassian et al., 2015). This SCCS was selected as it most closely represented the 
simulated cohort and was specific to a U.S. population. Because HZ infection itself is the 
mechanism behind the association with increased stroke risk, HZ vaccination efficacy was based 
on data supporting prevention of HZ infection only therefore efficacy and durability of the 
vaccine against PHN and BOI were not included.  
Evaluating the Results 
Assumptions were based on a U.S. private payer perspective. Costs were expressed in 
current U.S. dollars and utilities expressed as quality of life-years gained (QUALYs) and were 
discounted at 3% annually with ICER WTP thresholds of $50,000 and $100,000 per QUALY 
(Drummond et al., 2005; Gold, Marthe, R.. Siegel, Joanna, Russell, & & Weinstein, 1996).  
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Outcomes were synthesized to evaluate evidence-based recommendations for three 
important stakeholders to promulgate intervention strategies from this study. Scientific findings 
were translated into population health based intervention and dissemination strategies to improve 
decision making around appropriate vaccination of adults age 50-59 years at increased CV risk. 
Economic and health benefit findings were translated to the unique perspectives of three key 
stakeholders, payers, providers, and policymakers to aid in the development and implementation 
of appropriate practice and policy based intervention strategies. Private payers are increasingly 
relying on cost-benefit analysis for the purpose of containing healthcare costs while still 
delivering value based care and improving population health outcomes. In this analysis, private 
payers targeted costs and outcomes were calculated as per member per month (PMPM) costs 
associated with the intervention strategies (based on number of cases of HZ and IS avoided in the 
target population) providing additional information on which to assess appropriate and 
reasonably implemented cost-effective managed care intervention strategies aligned with PHM 
and quality metric outcome measures.  
Provider level focus was on creating awareness for both providers and patients to help 
identify patients at risk and support shared decision making regarding vaccination. For 
policymakers, research results informed the development of suggested changes to existing 
immunization policies, recommendations, and quality metrics for the purpose of driving 
improved population health through decreasing costs and disease burden associated with stroke 
among a population where CVD prevalence continues to grow. Considerations included a 
targeted strategy for at risk groups, universal age-based strategy, and utility of combination 
strategies, including discussion of public health versus population health impacts of targeted 
strategy for a non-communicable disease. Assessment of impact on patient out of pocket cost 
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was considered in relation to current Affordable Care Act (ACA) coverage for all universally 
recommended vaccines, which currently does not include HZ vaccination in adults 50-59 years 
of age. 
Manuscript Overview 
  The purpose of this study was to evaluate the cost-effectiveness from the payer 
perspective of a targeted HZ vaccination approach in a population of immunocompetent adults 
age 50-59 years with increased CV risk factors for whom the current HZ vaccine is FDA 
approved but not ACIP recommended. Utilizing the CEA results a white paper was developed 
for the purpose of informing health care intervention strategies directed at payers, providers, and 
policymakers. The results are presented in two manuscripts found in sections II and III. 
Manuscript One (found in Section II), Cost-Effectiveness Analysis of Targeted Herpes Zoster 
Vaccination in Adults 50-59 at Increased Cardiovascular Risk 
Manuscript Two- (found in Section III), Stroke Risk Reduction through Herpes Zoster 
Vaccination, a white paper translation of findings for payers, providers, and policymakers.  
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SECTION II: MANUSCRIPT ONE 
Title Page and Journal Selection 
Manuscript One Title: Cost-Effectiveness Analysis of Targeted Herpes Zoster Vaccination in 
Adults 50-59 at Increased Cardiovascular Risk 
Primary journal selection: Annals of Internal Medicine 
Reason for journal selection: This journal has a large readership that encompasses a broad array 
of health care providers and decision makers and is among the most highly cited journals in the 
world. This journal was selected because it publishes a variety of original research including 
cost-effectiveness analyses. Complete journal guidelines can be found at: 
http://annals.org/aim/pages/authorsinfooriginalresearch 
Secondary journal selection: Vaccines or Stroke 
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Background 
Herpes zoster (HZ) affects more than 1 million adults in the U.S. each year. HZ is a risk 
factor for ischemic stroke (IS) based on increasing evidence of significantly elevated short term 
risk following HZ infection persisting for up to twelve months. Stroke is the fifth leading cause 
of death in the U.S. - every 40 seconds someone experiences a stroke and every four minutes one 
of them will die. 87% of all strokes are ischemic. HZ vaccine is approved but not recommended 
in adults 50-59 years of age. To date there have been no studies to assess the IS related cost-
effectiveness of a targeted HZ vaccination strategy, either alone or in combination with a 
universal approach, in adults age 50-59 years who are at increased cardiovascular (CV) risk.  
Abstract 
Objective: Assess the cost-effectiveness of a targeted HZ vaccination strategy in adults age 50-
59 years who are at increased cardiovascular (CV) risk for ischemic stroke (IS) versus usual-care 
in this population. 
Design: Markov model (MM). 
Data Sources: Medical Literature. 
Target Population: Immunocompetent adults age 50-59 with increased CV risk. 
Time Horizon: Lifetime for individuals of median age of 55 through mortality to 100 years. 
Perspective: Commercial Payer Direct Costs. 
Intervention: Herpes Zoster (HZ) Vaccine. 
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Outcome Measures: Cost-effectiveness denominated in quality-adjusted life-years (QALYs) 
and the Incremental cost-effectiveness ratios (ICERs).  
Results of Base-Case Analysis: The incremental cost of targeted vaccination over usual-care 
was $30.59 per person with an ICER of $55,517 per QALY.  
Results of Sensitivity Analysis: Using deterministic and sensitivity analyses all variables 
produced ICERs less than $56,000 per QALY. The only variables associated with increased 
ICERs were costs of IS resulting from HZ and cost of treating HZ. 
Limitations: Rate of IS risk within one year of HZ infection was obtained using a cohort of U.S. 
Medicare participants aged ≥ 65 which represents an older population than the simulation model 
and does not represent a commercial payer population.  
Conclusion: Targeted vaccination of adults 50-59 years of age at increased CV risk is cost-
effective with an ICER of $55,517 per QALY, falling well within the generally accepted 
willingness-to-pay (WTP) threshold of $50,000 - $100,000. Moreover, these results demonstrate 
cost-effectiveness of a universal vaccination strategy in this population with an ICER of $55,523 
per QALY. Cost of stroke associated with HZ infection is substantial and this study demonstrates 
that HZ vaccination intervention in adults 50-59 years of age can mitigate both the IS risk and 
economic burden associated with HZ infection. 
Primary Funding Source: None. 
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Introduction 
Over the last twenty years incidence of herpes zoster (HZ) infection also known as shingles, has 
been increasing among adults for unknown reasons (Kenneth E Schmader & Dworkin, 2017). 
The economic burden of HZ is currently estimated at over $1 billion per year in the United States 
(U.S.) and is expected to increase as the susceptible adult population increases (Johnson et al., 
2016b). HZ is caused by a reactivation varicella zoster virus (VZV), chicken pox, and more than 
95% of adults carry the virus with a 1 in 3 lifetime risk of developing HZ (Warren-Gash et al., 
2017). Post herpetic neuralgia (PHN) is the most common side effect associated with HZ and 
occurs in 10-18% of patients and is defined as prolonged pain at the site of rash increasing the 
overall burden of illness (BOI)(Centers for Disease Control and Prevention, 2016b). HZ is a 
vaccine-preventable disease and in 2006 the FDA approved a live-attenuated vaccine (Zostavax 
®; Merck) for the prevention of HZ in adults ≥ 60 years with an expanded approval for adults 
age 50-59 years in 2011. Since 2006 rates of adult immunization for HZ have been modest, as of 
2015 more than two-thirds of the U.S. population ≥ 60 are still unvaccinated and more than 94% 
of those between age 50-59 years have not received vaccination (PJ.Lu et al., 2017; Williams et 
al., 2017).  
Suggestion of an association between HZ and stroke was reported as early as the late 1950’s 
(Nagel & Gilden, 2015), since then epidemiologic evidence from self-controlled case studies, 
population based cohort studies, systematic literature reviews, and meta-analyses have confirmed 
a causal relationship between HZ infection and stroke thus establishing HZ as a stroke risk factor 
(Breuer et al., 2014; Kang, Ho, Chen, & Lin, 2009b; Kwon et al., 2016; Langan, Minassian, 
Smeeth, & Thomas, 2014b; Lian et al., 2017; Liu et al., 2016; Marra, Ruckenstein, & 
Richardson, 2017b; Minassian et al., 2015; Nagel et al., 2017; Schink, Behr, Thone, Bricout, & 
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Garbe, 2016; Sreenivasan et al., 2013; Sundström et al., 2015; Yang et al., 2017; Yawn et al., 
2016; Zhang, Yanting; Luo, Ganfeng;Huan, Yuanwei; Yu, Qiuyan; Wang, Li; Li, 2017b). This 
association is further supported by the pathologic mechanism between VZV infection and 
vasculopathy. VZV is the only recognized human virus that can replicate in the cerebral arteries 
thus producing viral arterial infection resulting in vascular inflammation and remodeling which 
can lead to stroke (Nagel & Gilden, 2015; Nagel et al., 2017; Powell et al., 2015; Warren-Gash 
& Breuer, 2017; Wu, Lin, Sung, Chou, & Yuan-Teh, 2014).  
Beginning in late 2016 several meta-analyses began appearing in the medical literature, further 
validating evidence of significantly elevated risk of stroke, specifically ischemic stroke (IS) 
within 12 months following infection with HZ (Lian et al., 2017; Liu et al., 2016; Marra et al., 
2017a; Yang et al., 2017; Y. Zhang et al., 2017). Currently the Centers for Disease Control and 
Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) recommend 
universal HZ vaccination only for adults ≥ 60 years. Prior HZ vaccine cost-effectiveness studies, 
which have largely informed the ACIP recommendations, have not included assessment of the 
associated risk of IS.  
Stroke strikes someone in the U.S. every 40 seconds with an estimated 795,000 strokes per year. 
Stroke is a significant cause of disability with costs estimated at $33 billion per year including 
cost of health care, medication, and lost productivity (Centers for Disease Control and 
Prevention, 2016d). As the U.S. population ages rates of HZ infection and stroke incidence will 
increase significantly impacting morbidity, mortality, and health care costs. The ACIP does not 
currently recommend vaccination for adults age 50-59 years and has not issued guidance or 
recommendations for adults who may be at increased risk of stroke associated with HZ infection. 
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Information on duration of protection and cost-effectiveness of HZ vaccination in persons age 
50-59 years are limited. Efficacy of the vaccine in adults age 50-59 years is estimated at nearly 
70%, based on data from the Zostavax Efficacy and Safety Trail (ZEST) however duration of 
vaccine protection was considered short term at 1.5 years (Kenneth E Schmader et al., 2012). 
Previous cost-effectiveness studies of Zostavax® in patients age 50-59 years have not 
demonstrated good value because they exceeded the generally accepted WTP threshold of 
$100,000 per QALY (Le & Rothberg, 2015). Understanding the risks, costs, and disutility 
associated with potential IS after HZ infection in this cohort for whom the vaccine is approved 
but not recommended is important for informing prevention strategies. Informing payers, 
providers, and policymakers is additionally important because adults age 50-59 are 
predominantly employed and covered under private insurance plans and would incur additional 
lost productivity from both HZ and IS. 
Methods 
  A decision analytic tree and Markov Model (MM) were used to compare costs and 
outcomes between two HZ vaccination strategies; usual-care (no current vaccine 
recommendation) and targeted vaccination in adults age 50-59 years with cardiovascular disease 
(CVD) in a hypothetical cohort of 100,000 adults age 50-59 years. The model structure was 
adapted from a previously published MM which assessed the cost-effectiveness of HZ 
vaccination versus no vaccination in healthy immunocompetent adults age 50-59 years (Le & 
Rothberg, 2015). Inputs were revised as necessary to assess the benefits of a targeted vaccination 
approach aimed at reducing IS risk in patients 50-59 years of age with cardiovascular disease 
(CVD).  
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The private payer perspective was used as it best represents this population of adults age 
50-59 years who are predominately employed and covered under employer sponsored 
commercial insurance. The decision analytic model stratified the two treatment strategies and the 
MM was employed to age the cohort to death or 100 years in order to calculate the difference in 
QALYs through mortality using a cycle length of one year. The simulated cohort was assessed 
for incidence of IS within 12 months following HZ infection occurring within the fifth decade of 
life. Risk was assessed from the age at entry to the analysis, median age 55, up to age 60 using 
TreeAge Pro 2017 software. The model assumed patients were immunocompetent and evaluated 
only direct costs associated with HZ infection and/or IS.   
The cohort entered the model at age 50 in a “healthy” state in either the usual-care arm or 
the targeted increased CV risk population arm moving between health states and transition 
probabilities up to age 60. Both arms, usual-care and targeted at risk population were stratified as 
vaccinated versus non-vaccinated. Disutility for IS was assumed for a one-year period, for 
subsequent years stroke disutility persisted. Disutility for HZ was calculated at two months. All 
costs were expressed in 2016 U.S. dollars and costs and QALYs were discounted at 3% per year.  
  Outcomes included costs and effectiveness for each strategy. ICERs reflect the cost-
effectiveness of the difference in costs between the intervention strategies divided by the 
difference in health benefits obtained and were then evaluated against the generally accepted 
WTP threshold of $50,000 to $100,000 (prior HZ CEAs used WTP of $100,000) (Le & 
Rothberg, 2015, 2016; Pellissier, Brisson, & Levin, 2007; Rothberg, Virapongse, & Smith, 2007; 
Szucs, Pfeil, Szucs, & Pfeil, 2013).  
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Model Inputs and Assumptions 
A systematic review of the literature and data sources was performed to update any 
parameters that may have changed since 2015 and to identify the most current and appropriate 
values for the model. Data used for the model were derived from U.S. based epidemiologic and 
statistical data sets and medical literature data and reflect disease incidence, costs, and QALYs 
expected in the general U.S. population. Table 2 describes estimates used for the base-case 
analysis including the deterministic and probabilistic sensitivity analyses parameters used for the 
simulated cohort of 100,000 commercially insured adults age 50-59 years.  
Epidemiologic Parameters 
 For reasons which are still unclear, over the last 20 years rates of HZ infection have been 
increasing across all age groups, even in the wake of a highly effective pediatric varicella 
vaccination program (Kenneth E Schmader & Dworkin, 2017). More recent epidemiologic 
incidence data of HZ in adults 50-59 years of age from Johnson and colleagues report a higher 
incidence among this population than previous studies and is consistent with data demonstrating 
increasing incidence of HZ across all age groups (Hales, C.M., Harpaz, R., Ortega-Sanchez, I., 
Bialek, 2014; Johnson et al., 2015). Estimates for vaccine coverage in adults age 50-59 years is 
limited due to a lack of an ACIP recommended and subsequent slow adoption in this age group. 
Data from the 2014 Behavioral Risk Factor Surveillance Study (BRFSS) was used to estimate 
vaccination rates in this population because this was one of the few resources available to obtain 
immunization rates in this population as data on 50-59 year olds is not included in the annual 
National Health Interview Survey (P.J. Lu et al., 2017). Incidence rates remained constant  
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Table 2: Parameters for Distributions Used in Base-Case and Sensitivity Analysis 
          Category Base-Case Value Sensitivity Analysis 
     Range                  PSA    
Distribution           Source 
HZ Incidence per 1000 person-years 
Population Aged 50 -59 years 
Males Aged 50-59 years 
Females Aged 50-59 years 
 
MORBIDITY 
Deaths due to HZ per 100,000 cases 
Population Aged 50-59 years 
Stroke Mortality 2014 age adjusted 
death rate per 100,000 
 
 
0.00674 
0.00501 
0.00835 
 
 
1.26 
 
36.5 
 
 
 
 
 
 
0.86 to 1.67 
 
CI 6.66-6.82 
CI 4.92-5.11 
CI 8.24-8.47 
 
 
Bernoulli 
 
 
 
 
 Normal 
 
Johnson, 2015 
HZ Vaccination Rates 
Population Aged 50-59 years 
 
5.90 
    
  Beta 
 
Lu et al, 2016          
       
Vaccine Efficacy 
Population Aged 50-59 years 
 
Vaccine AE’s 
Local reaction 
Serious reaction 
 
CVD Prevalence 
Population Aged 40-59 years 
Males Aged 40-59 years 
Females Aged 40-59 years 
 
 
Stoke Risk within 1 year of HZ  
Population 50-59 years 
Males Aged 50-59 years 
Females Aged 50-59 years 
 
 
Health Utilities 
HZ positive 
HZ positive- Stroke positive 
 
Direct Medical Costs, $/case 
HZ Adults 50-59 
IS Acute and long-term over 
360 days post discharge 
 
Mortality 
 
59.50% 
 
 
0.64 
0.001 
 
 
36.60% 
41.4% 
39.4% 
 
 
 
12.20% 
3.54% 
8.66% 
 
 
 
0.87 
0.65 
 
 
$1614 
 
$29,364 
 
Background   
 
 
 
 
 
0.63 to 0.65 
0 to 0.003 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
(7088; 4004) 
(0.96; 957.48) 
 
 
 
 
 
 
 
 
 
 
 
Normal 
 
 
Beta 
 
 
 
Normal 
 
 
 
 
 
Beta 
 
 
 
 
 
Normal 
 
 
 
Gamma 
 
 
 
Beta 
 
 
     
 Baxter et al, 2017 
 
 
 Le & Rothberg, 2016              
 
 
 
 Benjamin, 2017 
 
 
 
  
 
 Minassian, 2015 
 
 
 
 
 
 Le & Rothberg,  2016 
 Chan et al.,  2016 
 
 
  Johnson,  2016 
 
  Mu et al., 2017 
 
  U.S. Life Tables 
Vaccine Costs (2017 US$)  
Private Sector 
Administration 
  
Cost-Effectiveness 
Discount Rate 
Willingness to Pay (WTP) 
 
$212.66 
$25.00 
 
 
3.0% 
$50,000-$100,000 
    
Gamma 
 
 
 
Gamma 
 
 
CDC Price List 
 
 
 
  
HZ = Herpes Zoster;                                                                                                                                                                                      
IS = Ischemic Stroke 
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throughout the analysis and no adjustments were made for potential HZ recurrence which long-
term studies have reported as 5-6%. (Kawai, Gebremeskel, et al., 2014). Several studies have 
reported significantly higher incidence of HZ in adult women across all age groups (Johnson et 
al., 2015; Sundström et al., 2015), thus female gender is considered a risk factor for HZ (de Boer 
et al., 2014). The base-case analysis assumed equal gender distribution. The probability of death 
attributable to HZ for adults age 50-59 years was pulled from Le & Rothberg (2015).  
 IS incidence within one year of HZ infection was drawn from a 2015 self-controlled case  
series (SCCS) analysis of a U.S. Medicare population of adults ≥ 65 years with a HZ diagnosis 
and IS within defined time periods using data gathered between January 2006 and December 
2011 (Minassian et al., 2015). While there has been significant literature published on the 
associated risk of stroke after HZ infection, this SCCS was selected as it most closely 
represented the population being evaluating and was specific to a U.S. population (Erskine et al., 
n.d.; Kang et al., 2009b; M.C. Kim et al., 2017; Langan et al., 2014b; Lian et al., 2017.; Liu et 
al., 2016; Marra et al., 2017a; Yang et al., 2017; Zhang, Yanting; Luo, Ganfeng;Huan, Yuanwei; 
Yu, Qiuyan; Wang, Li; Li, 2017b). Using this data, risk of stroke in the year following HZ was 
calculated at 12.20%, far below other reports of 30% or greater risk across various age 
populations(Gilden, Nagel, Cohrs, & Mahalingam, 2013; M.C. Kim et al., 2017). Age specific IS 
prevalence rates in the general population for those age 45-64 and CVD prevalence rates in the 
general population age 40-59 years were derived from the most current AHA heart disease and 
stroke statistics, specific IS and CVD prevalence data for the 50-59 year old population was not 
available (Benjamin et al., 2017). IS mortality was based on 2014 age adjusted death rate per 
100,000. 
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 Adults age 50-59 years have lower overall rates of HZ compared to older age groups and 
have a lower probability of PHN once they develop HZ (Le & Rothberg, 2015; Yawn BP., 
Saddier P., Wollan PC., St. Sauver JL., Kurland MJ., 2007). HZ infection is the primary risk 
factor for increased stroke risk associated with VZV vasculopathy (Nagel & Gilden, 2014, 2015; 
Nagel, Jones, & Wyborny, 2017). While prior CEAs considered direct and indirect costs 
associated with HZ infection as well as PHN and overall BOI, this analysis evaluated the direct 
private payer costs associated with HZ and efficacy of the vaccine for the prevention of HZ 
infection alone and did not include PHN or BOI.  
Vaccine-Related Parameters 
 CEAs for HZ are highly dependent on the age of vaccination and presumptions about 
duration of protection (durability) of the vaccine (Kawai, Preaud, et al., 2014). The ACIP 
recommendations for use of Zostavax® have heavily relied on cost-effectiveness results in 
patient’s ≥ 60 due to the preponderance of the data in this population. Previous cost-effectiveness 
studies of Zostavax® in patients age 50-59 years have not demonstrated good value based on the 
generally accepted WTP threshold of $100,000 per QALY due in large part to limited data on 
duration of efficacy in this population (Le & Rothberg, 2015). The 2015 CEA by Le and 
Rothberg estimated the long-term efficacy of Zostavax® in adults age 50-59 years by combining 
data sources from ZEST and LTPS and establishing a waning efficacy slope to project duration 
of protection (2015). More recent data has been cited as the preferred source for duration of 
efficacy for Zostavax®, specifically in the 50-59 year old cohort. Johnson, Jiang, Weiss and 
Graham (2017) conducted an analysis of six models of waning efficacy for the HZ vaccine and 
concluded that effectiveness data published by Baxter et al. (2017) should be used to predict 
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effectiveness and waning of the vaccine. Using this data, waning efficacy was assumed through 
the cohort up to age 60 regardless of the age at vaccination and was based only on reduction of 
HZ infection not PHN or BOI. Overall efficacy of the vaccine in this population was based on 
the ZEST efficacy of 69.8% (Kenneth E Schmader et al., 2012). 
Stroke-Related Parameters 
Meta-analyses of the associated risk stroke after HZ infection assessed independent risk 
of transient ischemic attack (TIA), ischemic stroke (IS), hemorrhagic stroke (HS), and 
myocardial infarctions (MI) and found consistent statistical significance associated with HZ 
infection and IS providing the basis for this analysis to focus on IS. 
Quality-Adjusted Life Years (QALYs) 
 Following Le and Rothberg (2015), this analysis incorporated the same utilities for HZ 
and utilities for IS were obtained from a recent analysis which specifically evaluated utility for 
the 12 months following stroke (Chan et al., 2016). All utilities were age adjusted and well 
utilities came from the 2001 Medical Expenditure Panel Survey and the 2001 National Health 
Interview Survey (Hanmer, Lawrence, Anderson, Kaplan, & Fryback, 2006). Utilities range from 
1.0 representing perfect health to 0 representing death. Per the manufacturer, serious adverse 
reactions with ZOSTAVAX® occurred at similar rates between vaccine recipients and controls 
and the most common reported adverse events were headache and injection-site reactions (Merck 
& Co., Inc. 2017). As reported adverse events associated with Zostavax® are limited with no 
cost specific interventions this model adopted the local and serious adverse reaction rates 
reported by Le and Rothberg (2015). 
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Costs 
Costs were based on direct costs from a payer perspective and were determined using the 
most updated information related to HZ vaccination and disease treatment burden in adults age 
50-59 years. Vaccine price was based on the private sector cost per dose published on the CDC 
vaccine price list and vaccine administration costs were aligned with the 2015 data presented by 
Le and Rothberg (Centers for Disease Control and Prevention, 2017b). Data on healthcare 
resource utilization and costs of HZ infection were gathered from a recent analysis by Johnson 
and colleagues who specifically reported data on adults age 50-59 years, and found that 
approximately 25% of HZ cases occur in this age group and have higher incremental than those 
in older age cohorts (Johnson et al., 2016b). The estimated healthcare utilization cost of $1,614 
included inpatient admissions, ER visits, outpatient office visits, and other outpatient services for 
HZ. Johnson and colleagues further commented that “…while the ACIP does not currently 
recommend vaccination of adults 50-59 years of age, HZ patients in this age range have a 
substantial stake in the overall economic burden of HZ” (2016, p.933). The reported incremental 
cost was reflective of HZ infection only and does not include PHN or BOI.  
A significant proportion of strokes occur in adults under age 65 and estimates suggest 
that by 2050 about half of stroke-related costs, including treatment, rehabilitation, and lost 
productivity, will be incurred in this age population (Wang et al., 2014). Most of the literature on 
cost analyses of stroke has been based on cost of hospitalization which typically comprises about 
50% of the direct costs. The analysis by Mu et al. assessed IS stroke costs including the time 
period after hospitalization from the commercial payer and patient out of pocket cost perspective 
(2017). Cost data was selected from Mu et al. because it was IS specific, included considerations 
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of costs as of 2015, reflects the increased use of recombinant plasminogen activator (rt-PA), and 
most closely approximates the perspective (commercial payer) and time period (one year post IS) 
used in this analyses. Because this study population is based on claims from a large commercial 
database, it predominantly captured patients ≤ 65 years of age since it did not include traditional 
Medicare claims (Mu et al., 2017). The average age of patients discharged with disability was 
64.4 years and 58.1 years for those discharged without disability. This study also examined CV 
comorbidities and found higher correlation between patients discharged with disability compared 
to those without disability. Although this study does not compart data specific to our 50-59 year 
old patient perspective we did find it comparable to data on IS hospitalization costs for patients 
45-64 reported by Wang and colleagues in 2014. In that analysis of hospitalization only (which is 
estimated at approximately 50% of overall costs) costs ranged from $19,000 – $21,386 (Wang et 
al, 2014). In 2008 using patient-level data Luengo-Fernandez, Gray, and Rothwell reported 
similar stroke costs for the follow-up period of 12 months with mean costs of $28,525 and 
median costs of &19,635 (2009).  
Sensitivity Analysis  
Deterministic sensitivity analyses for all model inputs with the ranges specified in     
Table 2 were conducted to assess parameter uncertainties. Factors with the greatest influence on 
the ICER are presented using a tornado plot (see Figure 4). In order to assess the uncertainty and 
implications for the results for all of the input parameters simultaneously we used a MC 
simulation of 100,000 hypothetical adults. Iterations of the simulation make random draws for 
each probabilistic parameter from the underlying distributions to account for the uncertainty and 
variation in the model parameters calculating expected costs for a fixed set of input parameters. 
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Probabilistic Sensitivity Analysis (PSA) was used to determine confidence in base case 
analysis, strategy selection, and confirm the variance in the deterministic parameters. The 
analysis was based on the two defined treatment options, targeted vaccination or usual-care and 
used distributions rather than pre-set values to generate separate distributions each time a new 
value is selected.  
Results 
Base-Case Analysis 
Compared to usual-care, targeting HZ vaccination in adults age 50-59 years with 
prevalent CVD was cost-effective with an increase in incremental quality-adjusted life 
expectancy of 0.000551 per QALY at an additional cost of $30.59 per person. The incremental 
cost of vaccinating the target population using a benchmark vaccination rate of 60% was $30.59 
per person compared to $12.98 in the usual-care group with incremental cost-effectiveness ratios 
(ICERs) of $55,517 and $55,470 respectively, falling far below the generally accepted HZ 
vaccine WTP threshold of $100,000 used in prior CEAs. Moreover, when comparing the cost of 
universal vaccination in the entire 50-59 year old cohort cost-effectiveness was maintained with 
an incremental cost of $176.51 and an ICER of $55,523 (Table 3).  
Sensitivity Analyses 
 The CEA results provided means and descriptive statistics for QALYs and costs for each 
strategy to calculate the ICER which was then compared to the generally accepted WTP 
thresholds. The parameters that were varied through various plausible ranges and their effects on 
the ICER are shown in Figure 4. All variables were assessed and variables with value of zero 
were excluded from the analysis. By demonstrating that the largest contribution variables, such 
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as the cost of vaccination, lower the ICER this data support the very conservative study 
approach. Stroke mortality was shown to increase the ICER if the efficacy of the vaccine 
declines. 
 
Table 3: Cost-Effectiveness of Targeted HZ Vaccination in Adults 50-59 with CV Risk 
Strategy  Proportion   
Vaccinated 
(%) 
Costs 
($) 
Mean 
Costs 
($) 
SD 
Incremental 
Costs ($) 
Effectiveness 
(QALY) 
Mean 
Effectiveness 
(QALY) 
SD 
Incremental 
Effectiveness 
Incremental 
Cost 
Effectiveness 
Ratio (ICER) 
No Vaccine 
 
Usual-Care 
 
Targeted  
 
0.00% 
 
5.90% 
 
19.80% 
$25.12 
 
$38.10 
 
$68.69 
 
 
6.6487 
 
93.5041 
 
 
 
$12.98 
 
$30.59 
26.376759 
 
26.376993 
 
26.377544 
 
 
1.4123 
 
1.4121 
 
 
0.000234 
 
0.000551 
 
  
 
$55,470.09 
 
$55,517.24 
Universal   100.00% 
 
$245.20  $176.51   26.380723  0.003179 $55,523.75 
          
No Vaccine – Currently not recommended for adults 50-59 
Usual-Care – Population 50-59 receiving vaccination without recommendation 
Targeted (Vaccination) – Population 50-59 at CV risk using target vaccination rate of 60% 
Universal (Vaccination) - Entire 50-59 age cohort 
QALY – Quality-adjusted Life Year 
 
Post hoc analysis  
To contextualize these results for the payer’s perspective, the number of cases of HZ and 
IS avoided in each treatment arm were calculated in order to quantify the disease burden avoided 
by adopting the targeted strategy which was superior in cost-effectiveness terms. The targeted 
strategy resulted in 162 fewer HZ cases per 100,000, which translates to a savings of $261,468 
when then divided by 100,000 resulted in a cost of $2.61 per member per year which equates to 
.22 per member per month (PMPM).  
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Figure 4: Tornado plot of the factors with the most influence on the ICER 
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The targeted strategy resulted in 14 fewer strokes per 100,000 which translated to savings 
of $ 411,096 which when divided by the 100,000 cohort equated to a cost of $4.11 per member 
per year and .34 PMPM. Both PMPM calculations are within reasonably expected thresholds for 
managed care companies to consider such an intervention strategy. These results further inform 
the U.S. payer perspective demonstrating this cost-effective intervention strategy and its impact 
on PMPM costs. 
Discussion  
HZ is a risk factor for stroke. Recent evidence signals significantly elevated short-term 
risk of IS following infection with HZ persisting for up to twelve months. Stroke is the fifth 
leading cause of death in the U.S. and every 40 seconds someone experiences a stroke and every 
four minutes one of them will die (Centers for Disease Control and Prevention, 2016). This is the 
first study known to assess the cost-effectiveness of targeted HZ vaccination, either alone or in 
combination with a universal approach in adults age 50-59 years who are at increased CV risk. 
This study demonstrated that targeted HZ vaccination in patients age 50-59 years at increased 
CV risk is cost-effective and thus should be taken under consideration by the ACIP to re-
evaluate the current lack of recommendation of HZ vaccination in this population for whom the 
vaccine is currently FDA approved but not recommended. Furthermore, this study showed that a 
universal vaccination strategy in the general 50-59 year old population is cost-effective which is 
largely attributable to the significant cost burden associated with stroke. These results are also 
informative to private payer’s population health management considerations for the 
implementation of standard protocols for adult immunizations. 
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The model assumed a 60% target vaccination rate in the at risk population which is twice 
that of the current HP 2020 benchmark for HZ vaccination in the current universal recommended 
population of adults ≥ 60 years. This value was selected because it mirrors the current 
pneumococcal vaccination HP 2020 goal for high-risk adults age18-64 years (see Table 1). This 
approach is supported by evidence of  successful increases in pneumococcal vaccination in an at-
risk populations through efforts to target that population using electronic health records and 
quality metrics such as hospital re-admissions (Schmaltz, Williams, Chassin, Loeb, & Wachter, 
2011). The results of this CEA are also informative to the establishment of HP 2030 goals for HZ 
immunization which are currently being developed. 
Decision analyses using simulation models to estimate cost-effectiveness of HZ 
vaccination are strongly represented in the literature (Le & Rothberg, 2015, 2016; Pellissier, 
Brisson, & Levin, 2007; Rothberg, Virapongse, & Smith, 2007) and are a useful tool to estimate 
cost-effectiveness without incurring the cost and time required to conduct a RCT. Previous cost-
effectiveness models in both the 50-59 and the ≥ 60 year old HZ vaccination cohorts have been 
instrumental in informing ACIP recommendations in these populations. Given that the evidence 
of increased risk of IS within one year of HZ infection has only recently begun to receive broad 
attention in the medical literature, this study may be the first to consider cost-effectiveness of a 
targeted vaccination approach for a specific at-risk population of adults age 50-59 years for 
which currently no recommendations or risk-based guidelines exist.  
The strength of these findings was confirmed by deterministic and probabilistic 
sensitivity analyses. Targeted vaccination of adults age 50-59 with increased CV risk resulted in 
an ICER under $60,000 per QALY as did universal vaccination of the entire 50-59 year age 
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cohort. This analysis is subject to several limitations. First, while there is now substantial 
literature on the HZ associated risk of IS, there was no available U.S. based specific data for IS 
risk after HZ representing adults 50-59 years of age using a private payer approach. The study 
conducted by Minassian and colleagues was selected because it most closely resembled the 
simulated cohort and was pre-specified to assess risk of IS related to HZ. As this study was in a 
Medicare population of adults ≥ 65, IS risk data was adopted from the stratified 65-69 year old 
population to most closely approximate the risk in our 50-59 year old cohort. Second, CVD 
prevalence data was from the larger 40-59 year old population since data on 50-59 year olds was 
not available.  
There are several strengths to the study, some of which were not present in prior CEAs 
for the 50-59 year old group. Updated incidence, disease burden, duration of vaccine efficacy, 
and direct healthcare utilization costs associated with HZ specifically in the 50-59 year old 
population have recently been reported and were updated for this analysis (Baxter et al., 2017; 
Johnson et al., 2015, 2016a). Additionally, recently published third-party payer direct costs 
associated with IS were also incorporated into this analysis (Mu et al., 2017). CV risk was 
assessed using CVD prevalence data which only represents those who have active diagnosed 
cardiovascular diseases (atherosclerosis, chronic heart disease (CHD), heart failure (HF), prior 
MI or stroke, etc.) and does not begin to consider the millions more Americans with one or more 
risk factors for CVD. Given that the current prevalence of CVD in adults ≥20 years is estimated 
at 36.6% and it is estimated that by 2030, 43.9% of the U.S. population will have some form of 
CVD (Benjamin et al., 2017). By this measure this approach represents a very conservative 
estimation of the population at increased CV risk. Additionally, considering these results 
demonstrated favorable cost-effectiveness in the 50-59 age cohort for  whom rates of HZ and IS 
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are lower than the ≥ 60 age cohort one could predict that increasing immunization rates in the 
present recommended cohort of adults ≥ 60 could provide substantial reductions in economic and 
disease burden associated with HZ and IS.  
 
 
Figure 5: Cost-Effectiveness of Targeted Vaccination 
 
In conclusion, targeted HZ vaccination in adults age 50-59 years with increased CV risk 
is cost effective with an ICER threshold of $55,517 far below the standard WTP applied to 
previous HZ vaccine CEAs. The incremental cost of vaccinating the at-risk population was 
$30.59 per QALY. Universal vaccination was also cost-effective at an ICER of $55,517 with an 
incremental QALY of $176.51 which while still cost-effective may not represent the highest 
value in a cost-constrained environment (see Figure 5). These findings are significant not only 
from a cost-effectiveness perspective but are critically necessary to inform payer, provider, and 
policymaker decisions aimed at improving healthcare delivery employing value based 
approaches focused on measureable outcomes while containing costs in order to improve overall 
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population health. The 2016 National Adult Immunization Plan specifically identified CEAs as a 
critical element of the plan because they “…help inform policymakers, health insurance plans, 
providers, employers, and the public about the value and importance of adult immunization and 
can inform decisions regarding promotion and reimbursement for adult immunization services 
(2016, p. 21).   
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Executive Summary 
In the United States (U.S.) adult vaccinations are highly underutilized, whereas rates of several 
adult vaccine-preventable diseases are increasing. Adult vaccines have been recognized as safe, 
effective and in most cases cost-saving if not cost-effective. Herpes zoster (HZ) is an example of 
one adult vaccine-preventable disease that has been increasing in incidence. A safe and effective 
HZ vaccine has been approved and in use for more than 10 years in the U.S. and yet only one-
third of the recommended population has been vaccinated. 
Evidence of an increased risk of ischemic stroke (IS) up to one year after HZ infection is 
accumulating in the medical literature. A significant portion of the U.S. adult population has 
existing cardiovascular disease (CVD), putting them at increased risk of stroke independent of 
HZ infection. This review evaluated the results of a cost-effectiveness analysis (CEA) of a 
targeted HZ vaccination approach in adults age 50-59 years with increased cardiovascular risk 
factors who would be eligible for preventive vaccination. This is a population for who the 
vaccine has been FDA approved but is not presently recommended by the Advisory Committee 
on Immunization Practices (ACIP). Based on these cost-effectiveness analyses (CEA) results and 
other findings in the literature the goal of this report is to translate this emerging science for 
dissemination to three key healthcare delivery and intervention stakeholder groups; payers, 
providers, and policymakers to guide informed decision making and coordinated adoption of 
effective evidence-based interventions aimed at increasing HZ vaccination among this 
population of at risk adults. 
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Introduction 
Adult vaccinations are significantly underutilized despite evidence of effectiveness and 
economic benefits (Jacob, Chattopadhyay, Hopkins, Morgan, et al., 2016;Williams et al., 2016). 
Rates of several adult vaccine-preventable diseases are increasing, specifically herpes zoster 
(HZ). HZ, also known as shingles, affects over 1 million people in the U.S. annually with a cost 
of over $1 billion. Lifetime risk of HZ is about 1 in 3 and rates of HZ among all age groups have 
been increasing for the last 20 years for reasons that are still unclear. Epidemiological evidence 
of an increased risk of ischemic stroke (IS) within one year of HZ infection is mounting. A 2015 
study using a U.S. Medicare database of adults ≥65 found a 2.4-fold increase in IS within the 
first week after HZ diagnosis followed by a gradual reduction in risk returning to baseline over 
the next six to twelve months (Minassian et al., 2015). HZ vaccine is FDA approved in adults 50 
years and older but is currently only recommended for adults aged 60 years and above largely 
based on CEAs which have demonstrated support for vaccination in the over 60 population but 
not in the 50-59 year old age group. 
Older adults are more likely to have chronic conditions and reduced overall health status 
and thus are more susceptible to diseases and are subsequently prone to greater risk of associated 
complications. Risk of preventable diseases and associated co-morbidities in adults will continue 
to grow as the aging population increases. The American Heart Association (AHA) projects that 
by 2030, 43.9% of the U.S. population will have some form of cardiovascular disease (CVD). In 
the U.S. stroke is the leading cause of serious long-term disability with annual costs (direct and 
indirect) of $33.9 billion. IS is among the leading causes of death, disability, hospitalization and 
healthcare expenditure in the U.S. (Mu et al., 2017). 
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The economic and societal burdens of HZ and IS are substantial therefore implementing 
cost-effective interventions such as vaccination could greatly improve population health goals 
and reduce costs. Effective and sustainable interventions to improve adoption and 
implementation of evidence based practices relies on three primary healthcare stakeholder 
groups; payers, providers, and policymakers. CEA of a targeted HZ vaccination approach in 
adults age 50-59 years with increased CVD risk has shown that such and intervention would be 
cost-effective. CEAs are an important component of healthcare expenditure prioritization and 
this new information should be rapidly disseminated for the purpose of communicating the 
economic and population health benefits of targeted vaccination in at risk adults.  
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Cost-Effectiveness Analysis Results  
 The purpose of cost-effectiveness analyses (CEAs) is to compare the costs and effects 
between two or more healthcare intervention alternatives as a means of determining if a new 
intervention or treatment strategy provides better health outcomes and to quantify the 
incremental costs associated with the additional benefits gained. Results of CEAs can be 
expressed in incremental-cost effectiveness ratios (ICERs) which are a dollar values assigned as 
a result of comparing costs between two intervention strategies divided by the difference in the 
quality-adjusted life years (QALYs) gained from those interventions. CEAs can also be used to 
calculate the number of cases of disease averted through adoption of the new intervention. The 
outcome measures provided from CEAs aid various healthcare decision makers in determining if 
new treatment or intervention alternatives should be adopted and if so, what are the costs 
associated with the new strategies relative to the benefits they provide. The resulting ICERs 
derived from CEAs are assessed against a standardized cost-effectiveness thresholds, defined as 
the amount of money the decision maker is willing to spend to gain one year of life, often 
referred to as wiliness-to-pay thresholds (WTP). Generally accepted WTP thresholds have been 
established for vaccine CEAs and range from $50,000 - $100,000. 
CEAs can help contain healthcare costs by assisting various stakeholders in making 
informed decisions to assess the value associated with adoption of alternative expenditures in 
healthcare. Recent evidence has shown a significantly elevated risk IS within one year following 
infection with herpes zoster HZ. To assess the costs and benefits of an intervention strategy 
aimed at reducing stroke risk in adults age 50-59 years for whom the vaccine is FDA approved 
but not recommended, a CEA was used to evaluated the difference between two intervention 
strategies; usual-care (no vaccine recommendation) compared to targeting adults age 50-59 years 
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who are at increased cardiovascular risk with a target of achieving a 60% vaccination rate in this 
group. The results of the analysis demonstrated cost-effectiveness with a cost per ICER of 
$55,470, which is well within the generally accepted WTP threshold for vaccine interventions. 
This study also provided results for the number of herpes zoster and stroke cases averted through 
adoption of the targeted vaccination intervention strategy. Number of cases avoided can also be 
translated into costs incurred by insurance payers as per member per month (PMPM) costs which 
is another useful tool for payers to assess overall budget and health impacts of the intervention. 
Incremental differences in PMPM costs associated with intervention strategies can be assessed 
relative to the cases of HZ and IS avoided and evaluated based on the anticipated costs of 
implementing the vaccination intervention strategy through a population health management 
(PHM) approach within the payers healthcare delivery universe. In addition to demonstrating an 
ICER of $55, 470 for the targeted intervention strategy, the CEA calculated the PMPM cost  of 
reducing 162 cases of  HZ in the intervention versus the usual-care arm at a cost of .22 PMPM 
and avoidance of 14 cases of stroke at a PMPM cost of .34. Both of these PMPM costs are within 
reasonably expected thresholds for insurance payers to consider adoption of the intervention 
strategy.  
 These findings are significant not only from a cost-effectiveness perspective but help 
inform payers, providers, and policymakers decisions to improve healthcare delivery 
interventions focused on measureable outcomes while containing costs to improve overall 
population health. These results inform the basis for this report to provide recommendations for 
the adoption of targeted HZ vaccination in at risk adults age 50-59 years with considerations for 
the associated costs relative the benefits gained through reduction in the number of cases of HZ 
and IS avoided. 
  
57 
 
The 2016 National Adult Immunization Plan (NAIP) specifically identified CEAs as a 
critical element of the plan because they “…help inform policymakers, health insurance plans, 
providers, employers, and the public about the value and importance of adult immunization and 
can inform decisions regarding promotion and reimbursement for adult immunization services 
(2016, p. 21).   
Background 
Slow Adoption of Evidence-based Strategies 
Dissemination and implementation of evidence-based research into practice is necessary 
to achieve optimal results and effectively apply research findings to improve outcomes (R. C. 
Brownson, Colditz, & Proctor, 2012). According to Balas and Boren it can take as long as 17 
years for evidence-based research to translate into clinical practice which can result in people 
experiencing significant delays in being offered interventions that have been proven to improve 
health (2000). Translating research into practice is a complex process that involves disseminating 
information to appropriate stakeholders, adoption of the appropriate interventions, and successful 
implementation into the health care delivery setting, and then establishing sustainability of the 
intervention. To address complex health issues, researchers, clinicians, and healthcare decision 
makers need to work together and share their knowledge and expertise to increase the number of 
evidence-based interventions that are implemented in real-world practices. Increasing the 
number of interventions that translate into practice can have a direct and positive impact on the 
public’s health by increasing access to approaches that have been demonstrated to improve 
health.  
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Adopting and implementing effective and sustainable interventions is critical to the 
success of improving health related outcome metrics which are increasingly being linked to pay-
for-performance standards. As the U.S. continues a shift from a fee-for-service (FFS) model to a 
value-based payment model, increased focus on quality metrics is driving more financial risk to 
payers and providers. As quality measures emerge as drivers of intervention prioritization, CEAs 
play an important role in assisting healthcare decision makers to examine the differences in 
magnitude associated with the costs of various healthcare interventions and/or treatments 
(Drummond et al., 2005). CEAs are also an important tool for health policy decision makers. In 
the U.S. the Advisory Committee on Immunization Practices (ACIP) is responsible for making 
vaccine recommendations and as such they formally conduct and include CEAs along with other 
types of evidence to formulate their recommendations. With regard to vaccine policy, it has been 
suggested that to make cost-effectiveness analysis a more practical tool, analysts should evaluate 
investments across multiple diseases and interventions and include the influences of 
nonmonetary constraints (J. J. Kim, 2011). Assessing and implementing effective evidence based 
interventions has relevance for payers, providers, and policymakers. CEAs are just one of the 
tools which can be used to aid in informing interventions to reduce the time it takes from 
evidence to adoption to implementation in order to quickly and efficiently improve population 
health outcomes. 
Herpes Zoster is a Risk Factor for Stroke 
HZ infection is increasing among all age groups for unknown reasons (Kenneth E 
Schmader & Dworkin, 2017). Herpes Zoster Virus (HZV), also known as shingles, is caused by 
a reactivation of the varicella zoster virus (VZV), commonly known as chickenpox. After initial 
infection with chickenpox the virus hides in the central nervous system allowing for potential 
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future reactivation of the virus as HZV. HZ is an inflammatory neurological infection affecting 
approximately 1 million people every year causing an estimated 96 deaths. HZ is characterized 
by a painful blistering rash that develops over 5 to 7 days and can be accompanied by prodromal 
pain and/or tingling sensations. The itching, burning rash appears unilaterally and does not 
ordinarily cross the spine or midline of the abdomen, typically affecting one to three dermatomes 
(Kenneth E Schmader & Dworkin, 2017).  
Approximately 95% of all people living today have been infected with VZV and an 
estimated 25-35% of those are at subsequent risk of reactivation of the virus as HZ (Warren-
Gash et al., 2017). After age 50 the risk of HZ infection increases, there are presently about 42 
million 50-59 year olds in the U.S. and approximately 25% of HZ cases occur in this age group 
(Johnson et al., 2016b). Lifetime risk of HZ in the United States is approximately 1 in 3 and 
while most people will have it only once it is possible to get the virus two or three times over a 
lifetime after initial infection with chickenpox, long-term studies show a 5-6% risk of recurrence 
(Kawai, Gebremeskel, et al., 2014). Several studies report significantly higher incidence of HZ in 
adult women across all age groups (Johnson et al., 2015; Sundström et al., 2015), thus female 
gender is considered a risk factor for HZ (de Boer et al., 2014). One in 4 people with herpes 
zoster are hospitalized due to complications which can range from mild to severe depending on 
the patient’s underlying immune status and other health risks (Centers for Disease Control and 
Prevention, 2016c).  
VZV is the only known virus with the capacity to produce pathologic vascular changes 
associated with stroke through infection of the cerebral arteries (Nagel & Gilden, 2015). HZ is 
the single most common infection of the nervous system in the U.S. (Warren-Gash & Breuer, 
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2017). There is accumulating evidence of an increased risk of stroke within one year of HZ 
infection (Kang, Ho, Chen, & Lin, 2009a; Langan, Minassian, Smeeth, & Thomas, 2014a; Lian, 
Zhu, Tang, Yang, & Duan, 2017; Liu et al., 2016; Marra, Ruckenstein, & Richardson, 2017a; 
Minassian et al., 2015; Yang et al., 2017; Zhang, Yanting; Luo, Ganfeng;Huan, Yuanwei; Yu, 
Qiuyan; Wang, Li; Li, 2017a). 
 Although the incidence of stroke increases with age, it can strike at any time. In 2009, 
34% of people hospitalized for stroke were under age 65 (Centers for Disease Control and 
Prevention, 2016d). There are an estimated 795,000 strokes per year in the U.S. and more than 
75% of those are primary strokes. Stroke is a significant cause of disability with costs estimated 
at $33 billion per year including cost of health care, medication, and lost productivity (Centers 
for Disease Control and Prevention, 2016d). Stroke occurs when the blood flow to the brain is 
interrupted, ischemic stroke (IS) results from an obstruction such a clot in a blood vessel leading 
to the brain while a hemorrhagic stroke (HS) results from a ruptured or broken blood vessel in 
the brain (Centers for Disease Control and Prevention, 2016). IS represents 87% of all strokes in 
the U.S. with HS comprising the remaining 13% (Benjamin et al., 2017). CVD is a significant 
cause of stroke and the AHA projects that by 2030, 43.9% of the U.S. population will have some 
form of CVD. Stroke is the leading cause of serious long-term disability with annual costs (direct 
and indirect) of $33.9 billion (Benjamin et al., 2017). IS is among the leading causes of death, 
disability, hospitalization and healthcare expenditure in the U.S. (Mu et al., 2017). 
Risk of stroke associated with HZ is thought to be mediated through vasculopathy 
resulting from active VZV infection in the cerebral arteries. VZV is the only human virus known 
to infect cerebral arteries and VZV can reactivate from the dorsal root ganglia and infect cerebral 
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arteries without spreading to the skin (Nagel & Gilden, 2015). Nagel and Gilden suggest that the 
frequency of stroke after HZ is likely underestimated because VZV can reactivate without 
evidence of rash, therefore there may not be a HZ diagnosis (2015). Several studies have 
identified HZ as a risk factor for stroke and Sreenivasan and colleagues identified evidence of 
long-term risk of stroke in people who develop HZ before age 60 (Kang et al., 2009a; Langan et 
al., 2014b; Minassian et al., 2015; Sreenivasan et al., 2013). 
In 2006 the FDA approved a live-attenuated vaccine (Zostavax ®; Merck) for the 
prevention of HZ in adults ≥ 60 years with an expanded approval for adults age 50-59 years in 
2011. Zostavax® was initially studied in adults ≥ 60 in the Shingles Prevention Study (SPS) and 
demonstrated a 51% reduced risk of HZ infection in that population. Protection against infection 
was greatest in patients 60-69 years of age with 64% efficacy, then declined in patients 70-79 
years of age to 41%, and in patients ≥ 80 vaccine efficacy was 18% (Oxman et al., 2005). 
Efficacy of Zostavax® was studied in patients 50-59 years of age in the Zostavax Efficacy and 
Safety Trial (ZEST) and demonstrated reduced risk of developing HZ by 69.8% (Kenneth E 
Schmader et al., 2012).  
In 2015, HZ vaccination uptake in the universally recommended adult population of ≥ 60 
finally achieved the modestly set Healthy People 2020 (HP 2020) goal of 30%, which is the 
lowest target rate for all recommended adult immunizations (U.S Department of Health and 
Human Services Office of Disease Prevention and Health Promotion, 2017; Williams et al., 
2017). The most recent data on HZ vaccination among the ACIP universal age based population 
report rates of approximately 30.6% for ≥ 60 years and 34.2% for those ≥ 65 years, with the 
lowest rates in the 60-64 age group at 21.7% (Williams et al., 2017). The lower rate in adults 60-
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64 is of interest because that age group is predominantly covered under commercial insurance 
(active in the workforce) compared to those over 65 where the vaccine is considered a pharmacy 
benefit under Medicare. Significant racial and ethnic disparities for HZ vaccination persists with 
immunization coverage being highest among whites for all age groups (Williams et al., 2017). 
Data on rates of HZ immunization for those under age 60 are less reliable because the ACIP does 
not recommend the vaccine for this age group. The most recent data collected by the CDC using 
the 2014 Behavior Risk Factor Surveillance System (BRFSS) reported coverage of 5.9% among 
adults age 50-59 years and cited that the lower coverage compared to other groups may be 
partially due to lack of an ACIP official recommendation (P.J. Lu et al., 2017).  
CEA for HZ are highly dependent on the age of vaccination and presumptions about 
duration of protection (durability) of the vaccine (Kawai, Preaud, et al., 2014). The ACIP 
recommendations for use of Zostavax® have heavily relied on cost-effectiveness results from 
patient’s ≥ 60. Information on duration of protection and cost-effectiveness of HZ vaccination in 
persons age 50-59 years are limited and studies in this population have not demonstrated cost-
effectiveness based on the accepted wiliness-to-pay threshold of $50,000 - $100,000 (Le & 
Rothberg, 2015; Rothberg, Virapongse, & Smith, 2007). Risk of stroke associated with HZ 
infection has not been considered in current ACIP recommendations. ACIP does not presently 
provide any guidance or recommendations around HZ vaccination for adults at increased stroke 
risk at any age. 
Increasing Cardiovascular Disease in an Aging Population  
 The 2017 AHA Heart Disease and Stroke Statistics update reports the prevalence of CVD 
in adults ≥20 years is 36.6% and project that by 2030, 43.9% of the U.S. population will have 
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some form of CVD (Benjamin et al., 2017). These data only represent those who have active 
diagnosed cardiovascular diseases (atherosclerosis, chronic heart disease (CHD), heart failure 
(HF), prior MI or stroke, etc.) and does not begin to consider the millions more Americans with 
one or more risk factors for CVD. The Framingham Risk Scoring criteria estimates risk of 
developing CVD or some component of CVD (such as coronary heart disease, stroke, peripheral 
vascular disease, or heart failure) over a fixed time period by assessing risk factors such as sex, 
age, systolic blood pressure, total cholesterol, high-density lipoprotein cholesterol, smoking 
behavior, and diabetes status and uses these “risk scores” to recommend interventions                 
(D ’Agostino et al., 2013). Stroke is the leading cause of serious long-term disability in the U.S. 
with annual costs of estimated at $33 billion per year including cost of health care, medication, 
and lost productivity. Lost productivity associated with HZ and stroke is greatest in the working 
population of adults under age 65 making effective interventions even more beneficial in this 
population. 
Risk-based Targeted Vaccination Strategies 
  A recent CEA of a targeted HZ vaccination strategy in adults age 50-59 years that are at 
increased risk of ischemic stroke associated with CVD may be the first to assess the increased 
risk of stroke within one year of HZ infection. CEAs lean toward supporting targeted vaccine 
programs aimed at persons with the highest risk of disease because they yield the greatest return 
based on disease averted calculated on cost per dose administered. Universal strategies in 
conjunction with targeted strategies have been shown to be most effective in reducing disease 
(Balicer et al., 2014; Hardt et al., 2016). Unlike influenza and pneumococcal viruses, HZ is non-
communicable therefore traditional herd protection afforded by universal vaccination does not 
convey the same public health benefit (Centers for Disease Control and Prevention, 2016b).  
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 Selecting a targeted approach to HZ vaccination has several strengths. First universal 
vaccination strategies are expensive and hard to implement and to date have shown very modest 
uptake in the universal population. Second, interventions strategies can be efficiently geared to 
identify at risk populations who tend to have more frequent contacts with healthcare providers. 
Finally and perhaps most importantly a targeted HZ vaccination program in at risk adults could 
serve as a primary IS risk intervention, not unlike statin use, a primary prevention for those with 
prevalent CVD and a secondary intervention for those who have had a prior event (stroke, MI). 
Risk based intervention strategies targeting groups with certain co-morbidities have been proven 
effective in improving influenza and pneumococcal vaccine rates (Task Force on Community 
Preventive Services, 2005). Vaccination of risk based groups has historically been intended to 
identify groups or individuals who are at increased risk of disease based on their clinical co-
morbidities, age, occupation, lifestyle or living conditions and for those whom the risks 
associated with preventable diseases could present serious complications and increased risk of 
death (Paolo Bonanni, 2007). 
Vaccines are Safe and Effective but Underutilized  
The contribution of vaccines to the reduction of infectious diseases and disease mortality 
is indisputable and has far reaching externalities beyond positive economic outcomes for 
healthcare delivery and society as a whole (Rémy, Zöllner, & Heckmann, 2015). Vaccination has 
been declared as the number one greatest public health advancement of the 20th century but adult 
vaccines are still drastically underutilized (Health and Human Services National Vaccine 
Advisory Committee, 2012; Centers for Disease Control and Prevention, 1999). Vaccines are 
often seen as a victim of their own success because as the threat of serious vaccine-preventable 
diseases diminish resulting from effective childhood vaccination programs individual risk 
  
65 
 
perceptions among adults decreases. The value of vaccines for adults is not merely derived from 
their role in prevention of disease but in long-term disease associated sequelae generating 
indirect impacts greater than disease prevention alone and methods to measure these impacts 
need to be adapted to these externalities (P Bonanni et al., 2014). 
Fear of adverse outcomes or illness caused by vaccination, inconvenience (including 
cost), and lack of awareness of the need for vaccination are some of the reasons for under-
vaccination of special populations (Doherty et al., 2016). Older adults are often unaware of the 
need for vaccination as a result of ineffective communication of vaccine recommendations to 
patients and providers or lack of specific recommendations and guidance from policymakers for 
at risk populations. Factors associated with vaccine uptake among older adults are; attitudes and 
beliefs around vaccination, strength of provider recommendations, vaccine safety and efficacy, 
and individual risk perception of disease susceptibility (Doherty et al., 2016). 
The first comprehensive National Adult Immunization Plan (NAIP) was released in 2016 
with the goal of improving adult immunization rates through public health and population health 
approaches in alignment with the established HP 2020 objectives (U.S. Department of Health 
and Human Services National Vaccine Program Office, 2016a). The plan structure is founded on 
four key goals, each with specific strategies and objectives to reach those goals to improve 
vaccine adoption across the lifespan (see Figure 6). The first and primary goal of the plan is to 
strengthen the adult immunization infrastructure and a key objective in that effort is to “generate 
and disseminate evidence about the health and economic impact of adult immunization, 
including potential diseases averted and cost-effectiveness with the use of current vaccines” 
(U.S. Department of Health and Human Services Vaccine Program Office, 2016, p.16). 
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Figure 6: NAIP Goals 
(U.S. Department of Health and Human Services National Vaccine Program Office, 2016a) 
 
Currently there is very limited data on the economic impact of adult immunizations, the NAIP 
calls out the need for this information as a “critically important element of the plan” (U.S. 
Department of Health and Human Services National Vaccine Program Office, 2016a). 
Barriers to Adult Immunization 
There has been much discussion and review for decades about factors associated with 
low adult immunization uptake. The NAIP was developed after a comprehensive review of the 
current state of the research around barriers to adult immunization with specific consideration of 
the changing policies and practices in the healthcare delivery environment, such as the affordable 
care act (ACA) and pay-for-performance metrics. A formal environmental scan was conducted 
as part of the NAIP to review all adult immunization recommendations and reports issued 
between 2005 and 2015 (U.S. Department of Health and Human Services National Vaccine 
Program Office, 2016a). The environmental scan included a stakeholder survey to identify 
current perceptions of barriers to adult immunizations (Department of Health & Services 
National Vaccine Program Office, 2016, p. 11). The goals of the plan have been developed 
around addressing these specific barriers (see Figure 7). Unlike pediatric vaccinations, 
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administration of adult immunization is complicated by many variables including varying age 
ranges for delivery of adult vaccines and variables such as different recommendations by age 
determined by a variety of risk factors. Adults also tend to see a larger variety of care givers and 
many do not have a defined medical home which complicates coordination of care. Disjointed 
care delivery also impacts appropriate record keeping for adult immunization status. The 
environmental scan included surveys and feedback from a variety of stakeholders, including 
payers, employers, research organizations, healthcare providers, and professional associations. 
Successful implementation of the plan will rely on contribution, coordination, and collaboration 
from a wide variety of private and public entities.     
Identifying and Tracking Appropriate Patients. Identifying and tracking adult 
immunization status impacts appropriate delivery of vaccinations. Reducing missed opportunities 
to immunize adults each time they see a healthcare provider can significantly improve delivery 
of adult immunizations (National Vaccine Advisory committee (NVAC), 2014). A key challenge 
is for the provider to have adequate patient immunization history at the site and time of patient 
care. In addition, many opportunities to vaccinate are missed because vaccination status is not 
routinely being evaluated at every physician visit or healthcare provider encounter (Hurley et al., 
2014). Immunization Information Systems (IIS) also referred as “registries” are “confidential, 
computerized, population-based systems that collect and consolidate vaccination data from 
vaccination providers that can be used in designing and sustaining effective immunization 
strategies” (Frieden, Jaffe, Stephens, & Thacker, 2012, p. 1005). 
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Barriers to Adult Immunization 
• Lack of coordination of adult immunization activities across all stakeholders, including 
multiple health care providers for adults 
• Lack of integration of vaccines into adult medical care 
•     Lack or underuse of administrative systems (e.g., immunization information systems  
      [IIS]) for documenting vaccination histories and identifying patients who are due for 
      vaccinations in medical records 
•     Skepticism regarding vaccine safety and effectiveness 
•     Inability to pay for vaccination as a result of lack of insurance or variable coverage  
      for recommended vaccinations across health plans 
•     Provider concerns about reimbursement and vaccine administration fees paid by  
       health insurers, which discourages some providers from stocking all adult vaccines 
•     Lack of public knowledge regarding the adult immunization schedule and the risks  
      and consequences of vaccine-preventable diseases; lack of awareness that adults are  
      supposed to receive vaccines other than the influenza vaccine 
•     Legal barriers at the state and federal levels (e.g., restricting which providers can  
      administer vaccines)  
•     Lack of and/or weak recommendations by health care providers 
•     Limited use of evidence-based strategies to improve vaccine uptake, such as  
      reminder-recall and related systems 
• Conflicting and inaccurate information about immunizations in mass media 
 
Figure 7: Barriers to Adult Immunization 
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As of 2012, the CDC reported most all states had an IIS with the exception of the District 
of Columbia (DC) and New Hampshire and only two states were not collecting adult 
immunization data as of 2012 (Connecticut and Rhode Island) (Frieden, Jaffe, Stephens, & 
Thacker, 2012). IIS’s have been an important technological tool to maintain patient level 
immunization data. A limitation for adults’ inclusion in registries is that adults are just now being 
migrated into the systems as they receive vaccines and prior vaccination histories for adults are 
not captured in these registries. The adoption of IIS reporting by other health care providers such 
as pharmacists has greatly assisted in the ability to communicate immunization status of adults 
between various providers since adults are more likely to seek care from more than one provider 
(Frieden et al., 2012). In many cases use of IIS is a mandatory requirement for alternate 
providers such as pharmacists.  
 In 2010 the Community Preventive Services Task Force (CPSTF) recommended the use 
of immunization information systems on the basis of “strong evidence of effectiveness in 
increasing vaccination rates” (The Community Preventive Services Task Force, 2010). 
Specifically the report outlined 5 capabilities provided by IIS’s that demonstrated effectiveness 
in improving immunization rates: (1) create or support effective interventions such as client 
reminder and recall systems, provider assessment and feedback, and provider reminders, (2) 
determine client vaccination status for decisions made by clinicians, health departments, and 
schools, (3) guide public health responses to outbreaks of vaccine-preventable disease, (4) 
inform assessments of vaccination coverage, missed vaccination opportunities, invalid dose 
administration, and disparities in vaccination coverage, and (5) facilitate vaccine management 
and accountability (The Community Preventive Services Task Force, 2010). 
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A limitation of IIS’s is that they are state based systems and do not have capacity to share 
immunization data between states and technical limitations exist for ease of transfer of data 
within and between health systems and providers. In 2012 in an effort to address appropriate use 
of IIS’s among all age groups the National Center for Immunization and Respiratory Diseases 
(NCIRD), a division of CDC introduced a strategic plan to facilitate that “real time, consolidated 
immunization data and services for all ages are available for authorized clinical, administrative, 
and public health users, and consumers, anytime and anywhere" (Centers for Disease Control 
and Prevention, 2015a). This project aims to maximize the use of health information technology 
through bi-directional information sharing between providers and state immunization registry 
databases allowing patient immunization records to cross populate between the registries and 
electronic health record systems. This enhanced capacity will allow for greater provider access to 
patient immunization status in order to more efficiently identify patients who have not received 
all recommended vaccinations. Interoperability between immunization registries and health care 
providers as well as complimentary immunization providers such as pharmacy’s will greatly 
assist in the identification of patients in need of immunization and over time as the databases 
become more robust they can have great utility to identify coverage trends and provide other 
epidemiologic surveillance data.  
Role of Vaccine Recommendations. Non-economic factors associated with barriers to 
adult immunization include activities facilitated within the provider’s office. As noted by the 
NAIP survey, lack of awareness of the need for adult immunizations, lack of a strong 
recommendation from a health care provider, and limited application of technology to support 
patient identification, physician flags, and reminder recall systems are a subset of barriers in and 
of themselves. One could also argue that skepticism about safety and efficacy, lack of public 
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knowledge about adult immunizations, and the role of media influences also have a place within 
the purview of the health care provider environment.    
Prior to the NAIP environmental scan, a multitude of studies had cited the importance of 
a strong provider recommendation as a key factor in improving adult immunizations rates 
(Hurley, Lindley, Harpaz, Stokley, & Daley, 2010; Bridges et al., 2015; Hurley et al., 2010). 
Strength of provider recommendation along with same day delivery of vaccination has been 
demonstrated as a proven strategy to improve adult immunization rates (National Vaccine 
Advisory committee, 2014). Factors which affect the strength of provider recommendations 
range from the lack of awareness on the part of the provider to a significant number of providers 
who do not stock routinely recommended vaccines for adults. If a physician is not stocking 
vaccines, they are far less likely to make recommendations or refer patients for ACIP 
recommended vaccines. Recent national recommendations including the 2014 National Vaccine 
Advisory Council (NVAC) report provides vaccine recommendation standards for all providers, 
including those who do and do not stock and or administer vaccines (National Vaccine Advisory 
committee, 2014).        
Disparities Associated with Adult Immunizations. Racial and ethnic disparities continue 
to persist in adult immunization coverage statistics. The 2014 NHIS found that for all seven 
vaccines evaluated, whites generally had higher immunization rates compared to other groups 
and rates were generally higher among those who reported having a regular place where they 
received their health care services (Williams et al., 2016). The gap in racial and ethnic disparities 
for children has been narrowing and in aggregate significant disparities do not exist. Possible 
factors contributing to better coverage among racial and ethnic groups for children are increased 
awareness of pediatric vaccines, better coverage programs for those who are un-insured or under-
  
72 
 
insured (vaccines for children (VFC) program), and school entry requirements (P. Lu et al., 
2015). Identifying and removing barriers that specifically impact racial and ethnic minorities can 
help improve immunization rates. For example from 2007 to 2012 when the availability of 
influenza vaccination in multiple settings was increased, gaps in influenza vaccination coverage 
reduced slightly in non-Hispanic blacks and Asians compared to non-Hispanic whites (Lu et al., 
2015, p. S423). Lu et al., recommend additional assessment of racial and ethnic disparities 
beyond data collected from National Health Interview Survey (NHIS) is needed (2015).   
    Role of Healthcare Coverage for Adult Immunizations. Lack of insurance coverage is a 
well-documented barrier to adult immunization coverage (Lu, O’Halloran, & Williams, 2015; 
Williams et al., 2016). For example in 2015, Lu, O’Halloran, and Williams reported that 
pneumococcal coverage for at risk adults between 18-64 years of age, for whom vaccination is 
routinely recommended, was 9.8% for uninsured compared to 23% for insured patients and 
influenza coverage rates were 14.4% versus 44.3% for uninsured versus insured (P.J. Lu et al., 
2015). Coverage for all ACIP routinely recommended vaccines was included as part of the 
ACAs essential health benefits which requires insurers to cover services within 10 benefit 
categories with limited out of pocket costs or no cost sharing for certain primary prevention 
interventions to facilitate improved population health. With the threat of “repeal and replace” this 
benefit may become a casualty of the current administration’s efforts to dismantle ACA. 
Costs and Coverage for Adult Vaccines   
Reimbursement for immunizations can be complex, even in the ACA era. The NAIP 
identified several barriers associated with cost of immunizations, these included patient concerns 
about out of pocket costs and insurance coverage as well as provider concerns about 
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reimbursement. The provider catch-all concern over “reimbursement” belies the many variables 
associated with vaccine reimbursement. Vaccines are somewhat unique in how they are 
delivered at the physician office level, vaccines for privately insured patients are acquired by the 
provider on what is often referred to as a “buy-and- bill” modality. Providers must purchase 
vaccines from the manufacturer or a third party distributor. Timing of when vaccines are actually 
paid for by the provider varies, some have delayed billing cycles with manufacturers and other 
vendors which allows time to get insurance reimbursements for administered vaccines, and some 
must pay for vaccines up front and wait for insurance reimbursement. In either scenario there are 
typically very large cost expenditures on the part of the physician to stock vaccines. 
Additionally, the more vaccines the provider stocks the more costly and challenging managing 
the vaccine inventory becomes. As more vaccines are added to the adult immunization schedule, 
the cost of providing all recommended vaccines continues to increase at the provider level. 
Hurley et al., identified insufficient stocking of all routinely recommended vaccines as a barrier 
to improving adult immunization rates (2014).  
Private patient insurance coverage for the “cost” of the vaccine can vary and in many 
cases can be less than the cost the physician pays to purchase the vaccine, known as “acquisition 
cost”. There are variable reasons for this, one can be price increases from the manufacturer 
which take time to get re-adjusted by the insurance provider or it may be an issue of contract 
negotiation between providers and payers. Providers consistently reference their overall cost of 
vaccines as a barrier (Bridges et al., 2015; Hurley et al., 2014). Providers have to manage the 
cost of the actual administration of vaccines. These “indirect costs” can include; the durable 
goods costs associated with administering vaccines (alcohol prep wipes, band aids, gloves etc.), 
personnel costs for ordering vaccines and providing adequate storage and handling (quality 
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control), storage costs, insurance against inventory loss, cost from wastage, non- payment and 
shrinkage (product lost to theft, or administrative or vendor errors), and lost opportunity costs 
(cost associated with maintaining a vaccine inventory) (American Academy of Pediatrics, 2012).  
In most provider’s offices vaccines are administered by a nurse or a medical assistant, 
rarely are vaccines ever administered by the physician. Most vaccine reimbursement 
arrangements have a provision to cover the cost of administration, however the standard 
reimbursement rate has not increased substantially over time and is typically far below the actual 
“real” cost associated with administration (athenahealth, 2011). Vaccines must be stored at 
specific temperatures and those temperatures must be monitored daily to ensure vaccine potency. 
Most vaccines must be refrigerated and some like varicella and herpes zoster vaccines must be 
kept frozen. All vaccines must be kept separate from food and other non-vaccine items so 
typically this requires a separate refrigerator and freezer (freezers must meet stringent 
temperature control requirements so a refrigerator/freezer combo is often unacceptable for this 
purpose) (Centers for Disease Control and Prevention, 2017d). All of these account for real 
economic and administrative costs for providers. 
Role of Alternate Providers in Delivering Adult Vaccinations 
The role of community pharmacists in the delivery of adult immunizations has increased 
dramatically as more adult vaccines are approved and recommended for use. Since the early 
1990’s pharmacists authority to administer vaccines has been steadily increasing. Currently 46 
states (including the District of Columbia and Puerto Rico) allow pharmacists to administer 
vaccinations. Authority varies by state as to whether or not pharmacists are permitted to 
administer immunizations without a prescription and which vaccines can be administered in the 
  
75 
 
pharmacy setting (American Pharmacists Association, 2015). Pharmacists are also actively 
participating in the use of state IISs partly due to the fact that in many states registry reporting 
was mandated as part of the legislation allowing vaccine administration authority. A challenge 
still remains for effective delivery of immunizations in the pharmacy setting due to the 
requirement for the pharmacy to be considered an “in-network” provider to process commercial 
insurance claims for patients. Efforts to close this gap are under way but there is still a long way 
to go to facilitate commercial insurance coverage in the pharmacy setting.  
Population Health versus Public Health  
 The distinction between public health and population health is not well understood, even 
among academics. Moving away from fee-for-service toward value based healthcare delivery 
provider and payers are facing increasing focus on cost-containment while also attempting to 
achieve measureable improvement in health related outcomes. Understanding how a population 
health approach differs from a public health approach is particularly informative to the 
intervention strategies we select and how we go about adopting and implementing them 
effectively and sustainably.  
The ACA has been a catalyst in moving the U.S. health care system from a public health 
approach to a population health approach and much of the evolution in health care policy reform 
is owed to Donald Berwick and the IHI for putting forth the Triple Aim, establishing focus and 
emphasis on improving the patient experience, reducing the cost of care, and perhaps most 
importantly focusing on improving the health of populations (D. Kindig & Isham, 2014). In 2008 
Berwick addressed the need to improve U.S. healthcare delivery, stating “the remaining barriers 
to integrated care are not technical; they are political” (Berwick, Nolan, & Whittington, 2008). 
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The Triple Aim demonstrated how to put population health into action and established a 
framework for population health management. 
Population health can be defined as health outcomes and their distribution in the 
population, and outcomes are achieved by patterns of healthcare determinants over the life 
course which are produced by policies and interventions at the individual and population levels 
(D. A. Kindig, 2007b, p. 141). Immunizations are recommended by a governing body (ACIP) 
and in some cases they are required (healthcare workers, school entry) so they can serve as a 
perfect example of where a healthcare intervention policy is directed at the individual but whose 
benefits of the outcome on the individual also accrue to the population (through herd immunity 
and reduced cost of treating disease), demonstrating a population health impact. 
Prior to the implementation of the ACA, more than 50% of adult deaths where associated 
with preventable diseases and approximately 95% of U.S. healthcare spending was for the 
treatment of chronic illness, including many preventable diseases, compared to 5% budgeted for 
health promotion and prevention (Nash, David et al., 2011, p. 7-8). Nash et al., suggest that 
presented with this data most policy makers, regulators, and politicians recognize the need for 
preventive care (Nash, David et al., 2011, p. 8). However, the challenge has been actually getting 
policymakers, payers, and providers to prioritize and effectively implement preventive care 
strategies like adult immunizations. There are real challenges in how each of these three key 
stakeholders would go about putting prevention at the forefront of healthcare delivery and cost-
effectiveness analyses are just one of the tools which can be employed to inform their decision 
making.  
  
77 
 
Without the tools and information to evaluate, measure, and translate outcomes from 
evidence-based public health interventions we are limited in our capacity to use that information 
to improve policies that drive improvements in population health. To emphasis the important role 
policymaking plays in improving health outcomes, Brownson, Chriqui, and Stamatakis cited the 
1999 review of the 10 great public health achievements of the 20th century, of which 
immunizations was number one, and they note that each of those important public health 
advancements was influenced by a policy change such as seat belt laws or regulations governing 
permissible workplace exposures (2009).  
Vaccine Quality Measures   
Implementation of influenza and pneumococcal vaccination performance measures 
among high-risk individuals have proven effective in improving vaccination rates both in 
hospital and ambulatory settings (Jha, Wright, & Perlin, 2007; Pennant et al., 2015; Schmaltz, 
Williams, Chassin, Loeb, & Wachter, 2011). Adult vaccination quality measures could not only 
improve population health through improved patient outcomes but also reduce costs to the U.S. 
healthcare system. There are currently two national projects underway which could establish 
quality metrics to drive improved delivery of adult immunizations (Appleby, Hodin, Satcher, 
Schaffner, & Perfetto, 2016). The Medicare Access and CHIP Reauthorization Act (MACRA) of 
2015, is part of the CMS payment reform aimed at shifting toward a volume based payment 
system which will require 90% of Medicare fee-for-service payments to be linked to quality by 
2019, pushing  financial risk to the provider level (Centers for Medicare and Medicaid Services, 
2017). This program is designed to incentivize providers to drive quality of care while reaching 
positive health outcomes and thus provides an appropriate foundation to establish adult 
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immunization measures. Also, America’s Health Insurance Plans (AHIP) and its member plans 
are collaborating with the Centers for Medicare and Medicaid Services (CMS), the National 
Quality Forum (NCF), national physician organizations, employers, and consumers on the Core 
Quality Measures Collaborative project to promote consensus on core performance measures 
(Appleby et al., 2016). As part of this collaborative, CMS has posted 7 proposed core measures 
which will go through a public notice and comment rule-making process before implementation 
(Centers for Medicare & Medicaid Services, 2017). It is particularly noteworthy that the 
currently proposed measures include pediatric vaccinations but make no mention of adult 
immunizations (comment periods have not yet opened). 
Recommendations/Solutions 
 This analysis has outlined the challenges, barriers, and benefits associated with adoption 
of evidence-based effective and sustainable interventions to improve adult vaccine delivery 
specifically for HZ which has been FDA approved but not ACIP recommended for adults age 
50-59 years. Based on recent evidence of significantly increased risk of IS within one year of HZ 
infection, across all age groups, and cost-effectiveness data supporting targeted HZ vaccination 
in adults age 50-59 years who are at increased CV risk, the most important place to begin putting 
forth recommendations and solutions to close the adult immunization gap is to successfully 
translate these findings from research into practice for payers, providers (and patients), and 
policymakers.  
Focus must be maintained on identifying measurable outcomes and prioritization of 
intervention efforts which yield the greatest population health impact. The following 
recommendations are suggestions to assist payers, providers, and policymakers to evaluate 
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various actions, practice, and policy changes which have been shown to influence adult vaccine 
adoption and delivery. Many of these interventions cannot be effectively implemented without 
the coordination and collaboration between the various stakeholder groups.  
 
  
  
80 
 
Stakeholder Specific Recommendations  
Payers 
 Evaluate cost-effectiveness data in support of targeted vaccination in the at risk 
population paying particular attention to the attribution of stroke risk with rising 
population prevalence of CVD, specifically in those under age 65 with increased 
comorbidities and in those with CV risk factors. 
 Conduct budget impact analyses evaluating per member per month (PMPM) costs of 
targeting at risk patients for HZ vaccination to establish intervention strategies. Which 
can be accomplished through; 
o Utilization of electronic health record patient identification flags. 
o Education to providers and patients about the increased risk of IS after HZ. 
o Utilize provider education venues and other established communication routes to 
inform and educate providers about increased risk of IS after HZ infection. 
o Generate patient directed information via electronic patient portals or print 
communications targeting at risk patients. 
 Select appropriate cost-effective intervention strategies and create dissemination 
frameworks to support sustainable efficient implementation of those interventions. 
 Collaborate with other stakeholders to evaluate opportunities to develop and link quality 
metrics to improvement of adult immunizations.  
 Adopt a population health management perspective to prevention interventions. 
 Establish in-network status for Pharmacies to allow them reimbursement for vaccine 
delivery.    
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Providers 
 Participate in grand-rounds, CME and other educational opportunities to learn more about 
the HZ IS risk association to better evaluate individual patient’s risks. 
 Proactively communicate risk of IS after HZ to appropriate patients and back it up with a 
strong vaccination recommendation. 
 Utilize electronic health record systems to integrate vaccination into routine workflow. 
 Institute standing orders for HZ vaccination in at risk patients. 
 Add HZ vaccination status to routine patient questionnaires at each visit. 
 Incorporate evaluation of HZ vaccination status in conjunction with annual influenza 
vaccine strategies. 
 Routinely educate patients about the risks of vaccine preventable diseases and the 
benefits of vaccination.  
 Be prepared to provide same day vaccination or provide a referral to an alternate 
provider. 
Policymakers 
 Support continued ACA coverage of routine vaccinations with no out of pocket costs. 
o Support funding mechanism for the uninsured 
 Evaluate the evidence of increased IS risk associated with HZ and consider possible 
policy changes which could impact improvement of HZ vaccine uptake.  
 Collaborate with other stakeholder groups to include adult immunizations as a core 
metric in the Core Quality Measures Collaborative performance measures which are 
presently under development and do not address adult immunizations. 
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 Roles for Health and Human Services (HHS) and Centers for Disease Control and 
Prevention (CDC); 
o ACIP:  
 Evaluate adding a risk-based recommendation for this population giving 
specific consideration to ACA coverage which does not extend to 
vaccinations that are not explicitly recommended by ACIP such as HZ in 
adults age 50-59. 
 Review CEA data on targeted vaccination in at risk adults and consider 
updating vaccine and stroke risk resources to reflect this associated risk. 
o Generate education of HZ associated IS risk through PSAs and social media. 
o Evaluate opportunities to communicate the increased risk of IS through other 
vaccine specific education and patient engagement campaigns.  
o Update Pink book and Vaccine General Recommendations to reflect this data. 
o Establish and promote effective immunization information systems with inter-
operability between providers, payers, and other vaccine delivery entities such as 
pharmacies. 
o Establish Healthy People HP 2030 guidelines including recommendations for HZ 
in at risk populations with benchmarks appropriately aligned to achieving 
population health goals to reduce adult vaccine preventable diseases. 
 NCQA, CMS, AHRQ, NQF; support adoption of quality metrics to improve adult 
immunizations such as; 
o Include evaluation of adult immunization in Medicare star ratings. 
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o Health effectiveness data and information set (HEDIS) measures for adult 
immunizations  
o Implementation of hospital based discharge metrics for age appropriate patients 
similar to those proved successful with pneumococcal immunization. 
 National Quality Forum (NQF); promote information of increased stroke risk with HZ 
and support adoption of performance measures to improve adult vaccine delivery.  
 National Adult Immunization Plan (NAIP); update plan to include HZ increased stroke 
risk information and cost-effectiveness of targeted vaccination in at risk patients. 
 NHLBI (National Heart Lung and Blood Institute) 
o Update stoke guidelines to include information on risk of IS and HZ. 
o Provide education and direction to providers on how to identify and recommend 
HZ vaccination in appropriate patients.  
 Medical society and vaccine advocacy groups endorsements, recommendations, and 
education. Examples include; 
o Immunization Action Coalition; develop educational resources and communicate 
risk of HZ and IS. 
o American College Physicians (ACP); update adult immunize resources to 
communicate risk of HZ and IS. 
o National Foundation for Infectious Diseases (NFID); Update resources and 
develop educational programs to inform members of associated risk of HZ and IS 
and encourage efforts to identify, promote, and deliver HZ immunizations to at 
risk populations. 
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Discussion 
Healthcare systems are under increasing strain to provide high quality care while 
maintaining healthcare costs. Establishing stakeholder awareness of the elevated risk of IS 
associated with HZ infection and the cost-effectiveness of a targeted intervention strategy is an 
important step in promoting primary prevention through vaccination of at risk adults.  
Many government agencies, organizations, and interest groups have established 
recommendations for addressing the gaps in adult immunizations and an effective population 
health management approach requires that we recall the fundamental difference between public 
health and population heath, which is a focus on measurable outcomes and the factors that 
influence them. Once selected, those measurable outcomes must be disseminated and 
implemented through efficient and sustainable intervention strategies requiring an in depth 
understanding of the determinants of implementation. The adoption and implementation of 
intervention strategies such as HZ vaccine recommendations for at risk populations and inclusion 
of adult immunizations in quality metrics are necessary to support efforts to promote primary 
prevention strategies, reduce healthcare costs, and improve population health. 
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SECTION IV: CONCLUSIONS AND RECOMMENDATIONS 
Study Implications 
 Epidemiologic evidence of increased stroke risk after HZ infection and the cost-
effectiveness of a targeted vaccination approach have been analyzed in the context of the various 
drivers and barriers to adult immunization adoption. Using a population health framework 
focused on measurable outcomes, these variables have been translated to provide intervention 
recommendations which can be achieved through changes in policy and practice.     
The volume of new research findings can exceed capacity to effectively evaluate their 
utility in a timely and cost-effective manner. Closing the gap between evidenced-based research 
and practice requires effective and sustainable dissemination and implementation intervention 
strategies. Translational researchers seek to identify the most beneficial and cost-effective 
evidenced-based strategies to improve population health. Tools like CEAs using simulated 
cohorts are a good way assess the various values associated with multiple intervention options in 
order to most efficiently identify those strategies that are likely to have the greatest likelihood of 
adoption by payers, providers, and policymakers. 
Study Strengths and Limitations 
This analysis is subject to several limitations. First, while there is now substantial 
literature on the HZ associated risk of IS, there was no available U.S. based specific data for IS 
risk after HZ representing adults 50-59 years of age using a private payer approach. The study 
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conducted by Minassian and colleagues was selected because it most closely resembled the 
simulated cohort and was pre-specified to assess risk of IS related to HZ. As this study was in a 
Medicare population of adults ≥ 65, IS risk data was adopted from the stratified 65-69 year old 
population to most closely approximate the risk in the simulated 50-59 year old cohort. Second, 
the CVD prevalence data was pulled from the larger 40-59 year old population since data on 50-
59 year olds is not available. However this analysis has several strengths, some of which were 
not represented in prior CEAs for the 50-59 year old group. Updated incidence, disease burden, 
duration of vaccine efficacy, and direct healthcare utilization costs associated with HZ 
specifically in the 50-59 year old population have recently been reported and were updated for 
this analysis (Baxter et al., 2017; Johnson et al., 2015, 2016a). Additionally, recently published 
third-party payer direct costs associated with IS were also incorporated into this analysis (Mu et 
al., 2017). CV risk was assessed using CVD prevalence data which only represents those who 
have active diagnosed cardiovascular diseases (atherosclerosis, chronic heart disease (CHD), 
heart failure (HF), prior MI or stroke, etc.) and does not begin to consider the millions more 
Americans with one or more risk factors for CVD. This point is significant given that the current 
prevalence of CVD in adults ≥ 20 years is estimated 36.6% and it is projected that by 2030, 
43.9% of the U.S. population will have some form of CVD (Benjamin et al., 2017). By these 
measures this CEA represents a very conservative estimation of the population at increased CV 
risk. Furthermore, bearing in mind that these results demonstrated favorable cost-effectiveness in 
the 50-59 age cohort for whom rates of HZ and IS are lower than the ≥ 60 age cohort one could 
predict that increasing immunization rates in the present recommended cohort of adults ≥ 60 
could provide substantial reductions in economic and disease burden associated with HZ and IS.  
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While this model provided the number of cases of both HZ and IS avoided in the targeted 
vaccination group based on a theoretical cohort, it was unable to specifically translate those 
results into reductions among the general U.S. population based on current HZ and IS incidence 
data. Future studies may benefit from adapting the results from the model cohort into real-word 
incidence reduction for the benefit of payer and policy decision makers, providing the capacity to 
consider interventions directly related to the potential impact on the real-world patient 
populations they serve.  
Selecting a targeted approach to HZ vaccination has several strengths. First universal 
vaccination strategies are expensive and can be hard to implement and to date have shown very 
modest uptake in the universal population. Second, interventions strategies can be efficiently 
geared to identify at risk populations who tend to have more frequent contacts with healthcare 
providers which is further facilitated by the increased use of electronic health records. Finally 
and perhaps most importantly a targeted HZ vaccination program in at risk adults could serve as 
a primary IS risk intervention, not unlike statin use, a primary prevention for those with 
prevalent CVD and a secondary intervention for those who have had a prior event (stroke, MI). 
Risk based intervention strategies targeting groups with certain co-morbidities have been proven 
effective in improving influenza and pneumococcal vaccine rates (Task Force on Community 
Preventive Services, 2005). Vaccination of risk based groups has historically been intended to 
identify groups or individuals who are at increased risk of disease based on their clinical co-
morbidities, age, occupation, lifestyle or living conditions and for those whom the risks 
associated with preventable diseases could present serious complications and increased risk of 
death (Paolo Bonanni, 2007). 
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Implications for Public and Population Health 
A common public health point of view of universal age-based vaccination strategies is 
that they are more feasible and less resource intensive. This may be true for vaccine interventions 
which provide additional societal benefits through herd protection. However, HZ is non-
communicable therefore; traditional thinking about benefits of vaccinating this population must 
be adapted to consider the individual risk from a population health perspective. HZ presents an 
interesting consideration in the realm of vaccination strategies which have always emphasized 
the benefits of herd protection. Because HZ arises from a virus that is already inside you and it is 
not communicable there are two significant strategies to be considered. First, primary prevention 
of VZV (chickenpox) can be obtained with pediatric and adolescent vaccination, over time this 
should reduce the susceptible adult population, so this approach fits into traditional thinking for 
public health interventions. Second, there is now an effective vaccine intervention to reduce risk 
of HZ in those who have already had chickenpox however unlike the public health approach to 
facilitate herd protection where the benefits accrue to the larger population HZ is non-
communicable so the benefits of vaccination translate at the individual and population health 
levels. Specifically with the new information of increased risk of stroke in an aging U.S. 
population with increasing rates of CVD, implementing effective strategies that provide the 
benefits of primary prevention for HZ infection and potentially stroke, vaccination could also 
serve as a secondary CV intervention strategy for reducing additional stroke risk in those already 
at risk. This population health approach accrues benefits at both the individual and societal 
levels. By reducing stroke risk and improving disease related outcomes at the individual level the 
benefits of reduced disease and healthcare utilization translate to the population, thus promoting 
population health. 
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The most significant population health related outcome from this analysis is the need to 
establish greater awareness of the IS stroke risk associated with HZ infection and as such 
generate greater focus on improving strategies to reduce that risk through effective vaccination 
of all CVD risk groups. There are multiple factors which determine population health; healthcare 
behaviors, genetics, socio-economics, and when it comes to population health policy the actors 
for this range of factors is spread across the public and private sectors (government at all levels, 
employers, healthcare organizations, school boards, community organizations). There is no one 
actor or agent accountable and responsible for such broad population health outcomes as 
mortality, morbidity and disparities making intervention strategies difficult to translate across 
these varied stakeholders (D. A. Kindig, 2014). The National Adult Immunization Plan (NAIP) 
has the lofty goal of improving adult immunization rates through public health and population 
health approaches in alignment with the established Healthy People 2020 objectives (U.S. 
Department of Health and Human Services National Vaccine Program Office, 2016a). Success 
of the NAIP relies on multifaceted, multi-stakeholder, public-private partnerships to achieve its 
goal of improving adult immunization uptake and delivery. 
The Role of Theory and Frameworks 
Translating the results of this study by applying the population health framework required 
evaluation of the role of health determinants and policy interventions (at the individual and 
societal levels) as they related to the health outcomes this research was attempting to address. 
The outcome measure was to evaluate if targeting HZ vaccination in at risk adults could be cost 
effective and determining cost-effectiveness included evaluation of how much HZ infection and 
HZ infection related strokes would be avoided in the vaccinated versus unvaccinated cohorts. 
Once this data is gathered it is not enough just to report out those findings, they must be 
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considered in the context of health determinants and policy interventions that would influence 
meaningful change in practice to facilitate increased adoption of vaccination. As noted, 
achieving population health improvements requires the collaboration between multiple partners 
which was the purpose of the relationship between the recommendations and solutions provided 
in the white paper addressed three different stakeholder groups.  
The population health framework approach is closely inter-related to implementation and 
dissemination models in that they are both seeking to improve adoption of evidence-based 
practices and reduce the time to adoption which improves overall population health. The 
recommendations and solutions for payers, providers and policymakers in the white paper were 
developed with the understanding of the need for a collaborative approach among the various 
stakeholders and how interventions are interdependent, for example without ACIP 
recommendation ACA coverage is not guaranteed, therefore ACIP recommendations must be 
implemented prior to expecting improvement in cost-related barriers to patient and provider level 
adoption. Understanding the roles various health determinants and policies play in influencing 
outcomes is necessary to developing recommendations for interventions which must then be 
effectively implemented and disseminated in order to achieve overall population health 
improvements. There is no one approach that works, it must be a thoughtfully considered 
collaboration with an understanding of implementation barriers and need for hierarchical 
intervention approaches in order to be sustainable and successful. 
Impact of this research is perhaps greatest for the cardiovascular world. Given that a large 
proportion of strokes occur in adults under age 65 and projections are that the cost of treating 
stroke in this population will account for half of all stroke related expenditures by 2050,  
understanding stroke risk and cost-effective intervention strategies such as targeted HZ 
  
91 
 
vaccination in at risk adults can not only aid in development of appropriate intervention and 
prevention programs but subsequently reduce economic and societal burden associated with the 
anticipated increase in stroke incidence (Wang et al., 2014). Introducing a cost-effective, 
evidence-based primary prevention strategy to reduce stroke risk in a population with escalating 
CVD prevalence resents an excellent example of the application of translating research into 
practice in order to improve population health. 
Implications for Commercial Payers 
With the introduction of the triple-aim and changes in the marketplace driven by ACA 
and the shift from volume to value, healthcare decision making power is now largely 
consolidated at the payer level. Focus on population health management (PHM) at the payer 
level requires informed decision making to guide the prioritization of multiple competing 
priorities. Efforts to communicate and promote the economic and health benefits of primary 
prevention strategies must be aligned to the perspective of the payer and demonstrate measurable 
outcomes relative to cost. Decision analytic models like the one employed in this HZ target 
vaccination CEA can be employed to inform managed care decision makers of the potential 
effects of costs relative to outcomes associated with the vaccination intervention strategy 
(Graham et al., 2016). Simulated decision analytic models provide a timely and cost-effective 
approach to evaluating multiple intervention approaches by providing insight to the number of 
cases of disease averted by the intervention and quantify how those interventions affect per 
member per month (PMPM) cost to the payer.  
In this CEA of targeted HZ vaccination of at risk adults age 50-59 years the number of 
cases of HZ and IS avoided in each treatment arm were calculated in order to quantify the 
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disease burden avoided when the targeted strategy was adopted which was superior in cost-
effectiveness terms. The targeted strategy resulted in 162 fewer HZ cases per 100,000, which 
translated to savings of $261,468 when then divided by 100,000 resulted in a cost of $2.61 per 
member per year which equates to .22 per member per month (PMPM). The targeted strategy 
resulted in 14 fewer strokes per 100,000 which translated to savings of $ 411,096 which when 
divided by the 100,000 cohort equated to a cost of $4.11 per member per year and .34 PMPM. 
Both PMPM calculations are within reasonably expected thresholds for managed care companies 
to consider such an intervention strategy. Translating these results in the form of budget impact 
analyses demonstrating the cost-effectiveness of this intervention strategy and its impact on 
PMPM costs can facilitate rapid decision making and support more timely adoption of evidence 
based intervention strategies. Expanded use of analytic models to demonstrate the value and 
benefits of adult immunization interventions through cost-effectiveness and budget impact 
analyses should be considered as they can play a significant role in aligning cost expenditures to 
anticipated outcomes and are a critical consideration for healthcare decision making among 
policymakers and payers (Bang & Zhao, 2014). 
Vaccination is generally believed to provide important public health benefits that also 
translate into positive economic outcomes which can significantly reduce the costs of treating 
disease (Rémy et al., 2015). Vaccination has also made significant contributions to the 
sustainability of healthcare systems by reducing the burden of infectious diseases and the 
resource use associated with them (Largeron, Lévy, Wasem, & Bresse, 2015). 
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Implications for Policy 
The adult immunization barriers identified in this analysis could be addressed through 
various policy approaches, some at the “big P” policy level such as formal laws, rules and 
regulations implemented by elected officials and some could be addressed through “small p” 
policies such as organizational guidelines, agency or system level decisions and social norms that 
guide behavior like education (Ross Brownson, Chriqui, & Stamatakis, 2009). The translation of 
these study findings into recommendations for each of the three key stakeholder groups includes 
both “big P” policies such as ACIP recommendations and “small p” policies such as patient 
recall and reminder interventions at the provider level. However, they are interdependent on each 
other, a change in recommendation by the ACIP is not sufficient unless “small p” policies 
changes are adopted to assure the practical compliance with “big P” policies. The policy making 
process is multifaceted and policies must not only be “technically sound, but also politically and 
administratively feasible” (Ross Brownson et al., 2009, P. 1578). Kindig states that one of the 
most critical issues facing us today is finding political and ideological common ground for 
improving population health (D. A. Kindig, 2015a). This is particularly important when 
successful adoption of intervention strategies relies on collaboration between multiple 
stakeholders. 
The National Quality Forum report on addressing performance measure gaps in adult 
immunizations tells us that quality metrics have to measure what matters most and our measures 
must be prioritized to strategically target those aspects of care that will promote the health 
outcomes we want to achieve. One of the challenges regarding measures for adult immunizations 
is that there is no one standardized measure utilized across the population health spectrum. CMS 
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Core Measures, HEDIS, Healthy People 2020 all establish performance measures for reaching 
adult immunization goals but the outcome goals are not unified nor are the metrics used to 
measure them. Additionally there is no hierarchy within these measures to assess them by level 
of importance or how achieving success in one area can facilitate success in another area of 
measure. There is no standardization across healthcare delivery segments (providers, hospitals, 
and payers) for adoption and implementation of quality metrics so it is difficult to optimize 
alignment of goals between these sectors. 
Informed by CEAs, the inclusion of appropriate adult immunization performance 
measures could serve to directly and indirectly improve other heath measures through the 
benefits of primary prevention, thus providing a significant population health benefit. Efforts 
such as the NAIP are helpful to improve awareness of adult vaccination for primary prevention 
and the plan specifically identifies adult vaccine CEAs as an unmet need in the ongoing efforts to 
inform decision making among payers, providers and policymakers.  
There are three areas where timely translation of these CEA results should be evaluated 
in the context of policy implications: First, the ACIP should evaluate this data and consider 
adopting risk based HZ vaccination recommendations or guidance for at risk adults. Second, the 
current Core Quality Measures Collaborative should evaluate this data to inform decision making 
around adoption of adult immunization metrics (which to date has not been considered). And 
finally the HP 2030 benchmarks are currently under development and they too should evaluate 
this information to inform achievable goals that are sufficient to promote population health. 
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Implications for Research 
While it is very encouraging that this analysis using Zostavax® demonstrated cost-
effectiveness not only for the targeted strategy but for the universal approach as well but perhaps 
even more encouraging is the recent approval and ACIP recommendation of a second HZ 
vaccine, Shingrix manufactured by GlaxoSmithKline for adults 50 years and over. Due to 
superior efficacy and anticipated longer duration of protection compared to Zostavax® the ACIP 
voted preferentially recommend the new vaccine for primary vaccination as well as re-
vaccination in patients who previously received Zostavax® (Lowes, 2017). In terms of research 
implications this new vaccine is a game changer in the context of cost-effectiveness analyses. 
While the new vaccine is a two dose series, efficacy in the younger age cohort is almost 100% 
out to four years of demonstrated effectiveness. Comparing those variables to the base case 
values used in this CEA, it is highly probable that the CE of Shingrix in an at-risk population 
would outperform the results in this analysis.  
Opportunities for timely evaluation of multiple parameters using this new vaccine are 
wide open and the current targeted CEA provides a strong foundation to develop additional 
simulation models to facilitate comparisons between the two vaccines and various intervention 
strategies and their respective cost-effectiveness. There are several parameters that would be of 
value to further investigate which were not included in the current analysis, one of which was 
gender differences in the incidence of HZ infection. The current CEA assumed equal gender 
distribution in both groups but the epidemiologic data report significantly higher rates of HZ in 
females, establishing female gender as an independent risk factor (Gilden, Nagel, Cohrs, & 
Mahalingam, 2013). 
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Conclusions 
Every year in the U.S. there are approximately 200 vaccine-preventable deaths in 
children compared to 70,000 vaccine preventable deaths in adults, translating to a 350 fold 
difference. With the aging U.S. population the number of adults ill or dying of vaccine 
preventable diseases will continue to grow (Paolo Bonanni et al., 2017). Achieving high adult 
immunization coverage necessary to provided improved population health and health outcomes 
can only be reached through coordinated stakeholder engagement and universal support of 
vaccine policies and adoption of evidence-based intervention strategies. 
  This CEA assessing a targeted HZ vaccination strategy in adults age 59-59 years at 
increased CV risk increased total health expenditures in the target population by $30.59 per 
person, compared with $12.98 for the usual-care population. Additionally the incremental 
expenditure for a universal vaccination approach was considered cost-effective at $176.51 
although this cost may not represent an acceptable intervention strategy relative to the value 
provided. The incremental cost to extend life by 1 QALY ranged from $55,470 - $55,523.00 for 
usual-care to universal coverage with vaccination being cost-effective in the target population at 
$55,517.24 per QALY which falls far below the established WTP threshold employed in prior 
HZ CEA.  
The overall societal value of vaccination is often not captured in traditional health-
economic measures of vaccine cost-effectiveness, socioethical contributions such as effects on 
health equity, sustaining the public good of herd immunity, and social integration of minority 
groups are often neglected in cost-effectiveness analysis (Luyten & Beutels, 2016). The value of 
preventing disease is hard to measure and even harder to promote in a way so that people can 
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appreciate the benefits of something they have never had to experience. This is perhaps what is 
most unique and challenging about efforts to communicate the benefits of vaccines to all 
appropriate stakeholders and decision makers. Schwartz and Mahmoud state in their 2016 
publication “When not all that counts can be counted; Economic evaluations and the value of 
vaccination”, that a better articulation of the value of vaccination could offer the potential for 
greater government attention and enthusiasm for vaccination programs (Schwartz & Mahmoud, 
2016).   
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APPENDIX A: LITERATURE REVIEW 
Herpes Zoster Epidemiology 
 Herpes zoster virus (HZV), also known as shingles is caused by a reactivation of the 
varicella zoster virus (VZV), commonly known as chickenpox. Rates of herpes zoster (HZ) 
infection are continuing to increase across all age groups despite the introduction of effective 
pediatric and adolescent vaccination programs for VZV (chickenpox) (Centers for Disease 
Control and Prevention, 2016c). Risk of HZ infection increases with age and those who have 
compromised or suppressed immune systems are at greater risk of infection and subsequent 
complications (Centers for Disease Control and Prevention, 2016a). HZ virus is an inflammatory 
neurological infection affecting millions of people every year and is characterized by a painful 
blistering rash. After initial infection with chickenpox, the virus becomes dormant in the dorsal 
root ganglia of the central nervous system. This latency allows for potential reactivation of the 
virus as HZ, which is thought to be brought on by advancing age or reduced immunity either 
through infection or increased stress to the immune system. Approximately 95% of all people 
living today have been infected with VZV and an estimated 25-35% of those are at subsequent 
risk of reactivation of the virus as HZ (Warren-Gash et al., 2017).  
 The HZ rash develops over 5 to 7 days and can be accompanied by prodromal pain 
and/or tingling sensations. The itching, burning rash appears unilaterally and does not ordinarily 
cross the spine or midline of the abdomen, typically affecting one to three dermatomes. The 
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annual rate of HZ in the U.S. is approximately 4 cases per 1,000 population which translates to 
about 1 million cases annually with a lifetime risk of developing HZ of 1 in 3 (Centers for 
Disease Control and Prevention, 2016c). While most people will have HZ only once, it is 
possible to experience the virus two or three times over a lifetime after initial infection with 
chickenpox. Long term studies show a 5-6% risk of recurrence (Kawai, Gebremeskel, et al., 
2014). Risk of HZ increases with age and in people ≥ 60 the rate is about 10 cases per 1,000 
annually (Centers for Disease Control and Prevention, 2016a). In 2015, Johnson and colleagues 
estimated rates of HZ in adults age 50-59 at 6.74 per 1,000 person-years (Johnson et al., 2015). 
Several studies report significantly higher rates of HZ in adult women across all age groups 
(Johnson et al., 2015; Sundström et al., 2015).  
The most common side effect of HZ infection is post herpetic neuralgia (PHN), which 
occurs in 10-18% of patients and is defined as prolonged pain at the site of the rash lasting at 
least 90 days following fading of the rash. PHN can persist for many months to years and can be 
debilitating. A potentially serious complication of HZ is Herpes zoster opthamalmicus (HZO), 
which occurs when the virus infects the ophthalmic region of the trigeminal nerve 
(approximately 15% of patients) and can cause chronic complications, including pain and 
possible loss of vision (Centers for Disease Control and Prevention, 2016a). Secondary 
complications such as bacterial infections and transmission of the virus to other susceptible 
individuals can occur (although this is rare and transmission would cause the primary VZV, 
chickenpox, not HZ) (Kenneth E Schmader & Dworkin, 2017). Complications from HZ can 
range from mild to severe depending on the patient’s underlying immune status and other health 
risks. Hospitalizations occur in 1-4% of those infected with HZ with an estimated 96 HZ- related 
deaths each year in the U.S. (Centers for Disease Control and Prevention, 2016c).  
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Herpes Zoster Vaccine  
Currently Zostavax® (Merck) is the only vaccine available for the prevention of HZ 
virus. Zostavax® was initially studied in adults ≥ 60 in the Shingles Prevention Study (SPS) and 
demonstrated a 51% reduced risk of HZ infection in that population. Protection against infection 
was greatest in patients 60 - 69 years of age with 64% efficacy, then declined in patients 70 - 79 
years of age to 41% , and in patients ≥80 vaccine efficacy was 18% (Oxman et al., 2005). 
Efficacy of Zostavax® was studied in patients 50-59 years of age in the Zostavax® Efficacy and 
Safety Trial (ZEST) and demonstrated reduced risk of developing HZ by 69.8% (Kenneth E 
Schmader et al., 2012). The Short-Term Persistence Sub-study (STPS) and the Long-Term 
Persistence Sub-study (LTPS), both conducted in patients  ≥ 60, have shown the vaccine is 
effective in reducing incidence of HZ, PHN, and overall burden of illness (BOI) up to 10 years 
post- vaccination (Morrison et al., 2015; K. E. Schmader et al., 2012). Post licensure studies 
assessing the durability of the vaccine to prevent HZ infection alone, not in combination with 
PHN and overall BOI), have shown declining protection for Zostavax® with evidence of vaccine 
efficacy through 5 years after vaccination and uncertain efficacy beyond 5 years (Morrison et al., 
2015; K. E. Schmader et al., 2012).   
Stroke Epidemiology 
Stroke is the 5th leading cause of death in the U.S., independent of other cardiovascular 
(CV) diseases, resulting in more than 133,000 deaths per year (American Heart Association & 
American Stroke Association, 2017). Although the incidence of stroke increases with age, it can 
strike at any time. In 2009, 34% of people hospitalized for stroke were under age 65 (Centers for 
Disease Control and Prevention, 2016d). There are an estimated 795,000 strokes per year in the 
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U.S. and more than 75% of those are primary strokes. Stroke is the leading cause of serious long-
term disability and the economic impact of stroke is estimated at $33 billion per year including 
cost of health care, medication, and lost productivity (American Heart Association & American 
Stroke Association, 2017; Centers for Disease Control and Prevention, 2016d). 
A stroke occurs when the blood flow to the brain is interrupted. An ischemic stroke (IS) 
results from an obstruction such a clot in a blood vessel leading to the brain while a hemorrhagic 
stroke (HS) results from a ruptured or broken blood vessel in the brain (Centers for Disease 
Control and Prevention, 2016). An estimated 87% of all strokes are ischemic (Mu et al., 2017). 
Rates of ischemic stroke have declined significantly in adults ≥ 60 between 2000 and 2010 while 
rates in adults 45-59 have remained essentially unchanged (Benjamin et al., 2017). Women have 
a higher lifetime risk of stroke although age-specific incidence rates are lower than men in 
younger and middle age groups but increase with advancing age. The prevalence of stroke 
survival among women is expected to increase as the population ages (Benjamin et al., 2017). 
Stroke Risk Factors 
 The National Heart Lung and Blood Institute (NHLBI) identifies primary coronary heart 
disease (CHD) risk factors as; hyperlipidemia, hypertension, diabetes and pre-diabetes, obesity, 
smoking, lack of physical activity, unhealthy diet, stress, age, gender, and family history 
(National Heart Association, 2016). Age, gender, and a family history of CHD are the only risk 
factors considered outside the control of the individual. Atherosclerosis, plaque buildup in the 
arteries leading to CHD, is thought to be caused by hyperlipidemia, hypertension, and cigarette 
smoking along with any prior coronary event such as heart attack or stroke are also risk factors 
for a coronary event. 
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Cardiovascular disease (CVD) includes numerous conditions affecting the heart and 
blood vessels including, CHD, acute myocardial infarction (AMI), atherosclerosis, and stroke  
(American Heart Association, 2017). In the U.S. approximately 92.1 million adults have some 
form of CVD or residual stroke sequelae. CVD accounts for 1 out of every 3 deaths in the U.S. 
each year, and claims more lives than all forms of cancer and chronic lower respiratory diseases 
with combined costs of more than $316 billion a year (direct and indirect costs). Stroke can 
cause long-term disability with approximately half of all stroke survivors suffering moderate to 
severe disability with cost of care estimated at $18.8 billion per year (American Heart 
Association & American Stroke Association, 2017). Lost productivity and premature mortality 
are estimated at an additional $15.5 billion (Frieden, Jaffe, Stephens, & Thacker, 2012). Diabetes 
increases risk of stroke incidence for all age groups however, ischemic stroke patients with 
diabetes tend to be younger, are more likely to be black, have hypertension, hyperlipidemia, and 
prior history of myocardial infarction (MI) than non-diabetics (Benjamin et al., 2017). 
HZ and Stroke Epidemiology 
 Evidence that HZ is a trigger for vascular events among certain populations is growing 
(Warren-Gash & Breuer, 2017) and may have first been described as early as 1896 (Nagel & 
Gilden, 2015). VZV is thought to be the only human virus that can replicate in cerebral arteries 
which can lead to productive infection causing vasculopathy and increased risk of ischemic and 
hemorrhagic stroke (Gilden, Nagel, Cohrs, & Mahalingam, 2013). The first studies to further 
investigate the association between VZV and vascular remodeling began in 1959 and more 
recent epidemiologic studies from three countries in Asia and Europe have established HZ as a 
significant risk factor for stroke (Nagel & Gilden, 2015). Nagel and Gilden suggest that the 
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frequency of stroke after HZ is likely underestimated because VZV can reactivate without 
evidence of rash, therefore there may not be HZ diagnosis (2015). The abundance of literature 
demonstrating HZ as a risk factor for stroke began appearing in 2009 predominately from cohort 
and case-controlled studies conducted in Taiwan, Demark, Sweden, United Kingdom (U.K.) and 
the U.S., each providing supporting evidence of a pronounced association between HZ and 
TIA’s, MI’s, and stroke within one year of infection with HZ (Breuer, Pacou, Gauthier, & 
Brown, 2014; Kang et al., 2009; Langan, Minassian, Smeeth, & Thomas, 2014; Nagel, Jones, & 
Wyborny, 2017; Sundström et al., 2015; Yawn, Wollan, Nagel, & Gilden, 2016). Recently meta-
analyses of these prior studies have been published further confirming the temporal association 
reported in the individual studies reporting relative risks for first month post virus ranging from 
1.55 to 1.94, and from 1.17 to 1.20 for 12 months post virus (Kang et al., 2009a; Lian et al., 
2017; Liu et al., 2016; Marra et al., 2017a; Yang et al., 2017; Zhang, Yanting; Luo, 
Ganfeng;Huan, Yuanwei; Yu, Qiuyan; Wang, Li; Li, 2017b).  Asserting that prior studies had 
not effectively accounted for confounding factors, Kim et al. (M.-C. Kim et al., 2017) conducted 
a propensity score-matched analysis using a Korean population database of over 570,000 people 
and reported confirmatory results from the previous analyses (2017). When adjusting for 
confounding this study reported a RR of stroke associated with HZ of 1.39 with a 95% 
confidence interval of 1.05-1.84 in adults 51-60, the study included additional age specific and 
CVD specific analyses (M.C. Kim et al., 2017).   
Adult Immunization  
Vaccination has been hailed as the most important public health advancement of the 20th 
century (Centers for Disease Control and Prevention, 1999). Vaccines for rabies, typhoid, 
cholera, and plague were developed before 1900 but had not been widely used. The period from 
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1900 to 1999 saw the most dramatic increase in not only the development of vaccines but also 
their widespread use (Centers for Disease Control and Prevention, 1999). Between 1900 and 
1999 there were 17 vaccines developed and approved for use and as a result, it was during this 
period that we witnessed the eradication of smallpox. In addition, there was a 99-100% decline 
in the number of cases of diphtheria, pertussis, tetanus, paralytic poliomyelitis, measles, mumps, 
rubella (including congenital rubella syndrome), and haemophilus influenza type b (HIB) 
(Centers for Disease Control and Prevention, 1999). Early emphasis on pediatric vaccination 
significantly reduced disease burden in children, and perhaps that is why today the true BOI 
from vaccine preventable diseases is greater among adults than for children (Bridges et al., 
2015).  
Biologically adults are at greater risk of acquiring vaccine preventable diseases due to 
overall reduction in the effectiveness of the immune system as we age, known as 
immunosenescence, which also reduces the robustness of vaccine immunologic response in 
adults (Gruver, Hudson, & Sempowski, 2007). The CDC reports that each year influenza causes  
more than 200,000 hospitalizations and between 3,000-49,000 deaths the majority of those (more 
than 75%) affected are adults, in addition there are approximately 900,000 cases of 
pneumococcal pneumonia each year with up to 400,000 hospitalizations and 19,000 deaths 
(Centers for Disease Control and Prevention, 2016e). Lu et al., reports that in 2012 there were 
approximately 3,300 patient deaths from invasive pneumococcal disease, 95% of these cases 
were in adults (P. Lu et al., 2015). Several vaccine preventable diseases are increasing in 
incidence among adults. In 2012 of the reported 41,880 cases of pertussis (whooping cough), 
9,000 were in adults, additionally there are about 1 million cases of herpes zoster reported each 
year (America’s Health Insurance Plans, 2015). High rates of disease in adults, also increases 
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cost of health care and creates additional burdens on healthcare services and delivery. In a recent 
analysis of the economic cost of four adult vaccine preventable diseases (influenza, 
pneumococcal disease, herpes zoster, and pertussis) the estimated annual cost of treating these 
diseases in adults 50 years and older is approximately $26.5 billion (McLaughlin et al., 2015).     
Immunization Recommendations  
 The Advisory Committee on Immunization Practices (ACIP) was established in 1964, 
under the direction of the Department of Health and Human Services (HHS) (Walton et al., 
2015). For the last 50 years this body of experts has been responsible for establishing 
recommendations for vaccine use and monitoring their safety and effectiveness. In 1984 the first 
attempt at developing formal recommendations for adult immunizations was undertaken by the 
ACIP and the American College of Physicians (ACP) (Walton, Orenstein, & Pickering, 2015).  
This initial “Guide for Adult Immunization” highlighted the use of four adult vaccines, tetanus 
and diphtheria, influenza, pneumococcal, (at least one dose of each vaccine for all patients but at 
differing ages) and hepatitis B (for at risk individuals) (Centers for Disease Control and 
Prevention, 1984). At this same time, the childhood immunization schedule recommended the 
use of vaccines to prevent seven infectious diseases; diphtheria, measles, mumps, pertussis, 
poliomyelitis, rubella and tetanus (Eickhoff, 1985). The 1984 recommendation guide also 
included discussions on the success of pediatric vaccination and notable emphasis was placed on 
the underutilization of adult vaccines. Furthermore, there was additional guidance provided 
around the  need to educate physicians and students about the importance of adult immunizations 
using a variety of medical education venues, including grand rounds, medical conferences, and 
consultation conversations (Eickhoff, 1985). Eight years later in February of 2002 the first ACIP 
schedule of routinely recommended adult immunizations for adults 19 years and older was 
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approved (Centers for Disease Control and Prevention, 2002). The schedule was established 
based on existing published recommendations from the ACIP, the American Academy of Family 
Physicians (AAFP), the American College of Obstetricians and Gynecologists (ACOG), the 
American College of Physicians – American Society of Internal Medicine (ACP-ASIM), and the 
Infectious Disease Society of America (IDSA) (Centers for Disease Control and Prevention, 
2002). These new recommendations included the four vaccines previously recommended in the 
guide published in 1984, and added hepatitis A (for at risk persons), measles, mumps, rubella 
(MMR) (1 dose for those who had no documented history of vaccination and 2 doses for those 
with risk factors), varicella (for susceptible people), and meningococcal (for persons with 
specific indications). This schedule also included a separate table which specified recommended 
immunizations based on certain medical conditions, including pregnancy, diabetes, and human 
immunodeficiency syndrome (HIV), among others (Centers for Disease Control and Prevention, 
1999a). When the approved schedule was printed in the Morbidity and Mortality Weekly Report 
(MMWR) in October of 2002 it also included recommendations for providers (family 
physicians, gynecologists, internists, and others) to assess vaccination opportunities during office 
visits and promoted the use of standing orders, patient reminder recalls, and provider reminder 
systems to decrease missed opportunities to assess vaccination status and administer appropriate 
vaccinations (Centers for Disease Control and Prevention, 2002, p. 905-906). Fifteen years later, 
these same recommendations to reduce missed opportunities continue to be a focal point in 
improving adult immunization rates. 
The current 2017 ACIP recommended immunization schedule for adults 19 years and 
older includes routine recommendation for eight vaccines based on various age requirements. 
Vaccination against Influenza, Tetanus, diphtheria, pertussis (Td/Tdap), and varicella are 
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recommended for all persons 19 years and older (unless other risk factors preclude vaccination). 
Human papillomavirus vaccination is routinely recommended for adult females up to age 26 and 
for adult males 19-21 years and for males up to age 26 with at risk conditions. Herpes zoster is 
routinely recommended for all adults over age 60, and two different pneumococcal vaccinations 
are recommended for all patients age 65 and over (Centers for Disease Control and Prevention, 
2017a). 
Efforts to Improve Adult Immunizations  
The Office of Disease Prevention and Health Promotion (ODPHP), a division of HHS, 
establishes the Healthy People 2020 (HP 2020) goals for immunization coverage and monitors 
progress annually based on results from the National Health Interview Survey (NHIS) conducted 
by the CDC. NHIS is an annualized household survey administered by the U.S. Census Bureau 
for CDC’s National Center for Health Statistics using in person interviews. Questions related to 
immunization status are addressed to one randomly selected adult within each household 
(Williams et al., 2016). NHIS collects data on the following adult vaccines; hepatitis A, hepatitis 
B, human papillomavirus, herpes zoster, pneumococcal, Td, and Tdap.    HP 2020 has 
established goals to improve rates for the following specific adult immunizations; pneumococcal, 
herpes zoster, and hepatitis B for health care personnel (U.S Department of Health and Human 
Services Office of Disease Prevention and Health Promotion, 2017). The most recent 
surveillance data from the 2015 NHIS concluded that adult vaccine coverage continues to remain 
low for most routinely recommended vaccines and current rates all fall below the HP 2020 goals 
(Williams et al., 2017).                               
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Between 1990 and 2010 multiple reports and recommendations were aimed at improving 
adult immunizations from a variety of agencies including; the National Vaccine Advisory 
Committee (NVAC), the Institute of Medicine (IOM), the Trust for America’s Health, and the 
Infectious Disease Society of America (IDSA), all aimed at improving adult immunizations, all 
with little to no impact or improvement (HHS National Vaccine Advisory Committee, 2012). 
Escalating focus on improving adult immunization rates began with the NVAC formation of the 
Adult Immunization Working Group (AIWG) in 2008. This group issued a report in 2009 
outlining recommendations to improve adult immunizations (HHS National Vaccine Advisory 
Committee, 2012). In response to the report, the Assistant Secretary for Health (ASH) directed 
NVAC “to develop recommendations for establishing a comprehensive, sustainable, national 
adult immunization program that will lead to vaccine preventable disease reduction by 
improving adult immunization levels” (HHS National Vaccine Advisory Committee, 2012, p. 1). 
A series of reports, recommendations, and workgroups soon followed. In 2010, HHS released 
the National Vaccine Plan (NVP) which outlined goals for improving vaccination for all people 
between 2010 and 2020 (U.S. Department of Health and Human Services National Vaccine 
Program Office, 2010).  
The National Vaccine Program Office (NVPO), a division of HHS is responsible for 
coordinating activities among various federal agencies with a range of responsibilities related to 
vaccines and immunizations (U.S. Department of Health and Human Services National Vaccine 
Program Office, 2017). It is the responsibility of NVPO to coordinate the activities and 
collaboration among these agencies in order to execute the strategies and goals outlined in the 
NVP. The NVPO is responsible for staffing NVAC, which was established in 1987 and is 
charged with oversight for recommendations for vaccine research and development, availability 
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and adequate supply, and direction for the prevention of vaccine adverse events. NVAC also 
makes recommendations to the ASH who also serves as Director of the NVPO on vaccine 
program related objectives (U.S. Department of Health and Human Services National Vaccine 
Program Office, 2017) Although all of these agencies have a role in making recommendations, 
setting priorities, and establishing goals and objectives for achieving improved prevention of 
vaccine preventable diseases through immunization, they lack any regulatory authority to require 
or mandate compliance with any of the recommendations set forth in the NVP. 
Even after the release of the NVP in 2010, rates for adult immunization uptake continue 
to lag far behind rates which would be needed to achieve herd protection and far behind goals 
established by HP 2020. Herd protection, or “community immunity” is achieved when a 
sufficient number of people in a population are immune to a communicable disease, either from 
immunization or prior disease exposure, such that the disease can not be easily spread from 
person to person (US Department of Health and Human Services National Institutes of Health 
National Institute of Allergy and Infectious Diseases, 2010). In follow up to the 2009 AIWG 
report and at the request of the ASH, in 2012 NVAC issued updated recommendations for adult 
immunizations. The report titled “A Pathway to Leadership for Adult Immunization: 
Recommendations of the National Vaccine Advisory Committee” identified nine categories of 
barriers to adult immunization and developed specific recommendations to address them. The 
report also identified additional adult immunization gaps and addressed those by developing five 
categories of recommended actions; (1) general infrastructure needs, (2) expanded access, (3) 
provider or system based interventions, (4) increasing community demand for vaccines and (5) 
research needs. (HHS National Vaccine Advisory Committee, 2012 p.1). Shortly thereafter, by 
2014 there was a need to update the recommendations again as a result of significant changes in 
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the adult immunization environment including outcomes and learnings from the 2009 H1N1 
influenza pandemic and healthcare changes driven by the Affordable Care Act (ACA) of 2010 
(National Vaccine Advisory Committee, 2014). 
National Adult Immunization Plan   
Another stimulus driving increased focus on adult vaccinations was the establishment of 
an annual National Adult and Influenza Immunization Summit (NAIIS). Previously an annual 
summit on influenza had been convened but in 2012, adult immunizations were added. NAIIS is 
a public private partnership of over 700 partner organizations, including NVPO, focused on 
improving adult immunizations. NVPO co-chairs the summit with in collaboration with the CDC 
and the Immunization Action Coalition (IAC) which is a private non-profit 501(c)(3) corporation 
(The National Adult and Influenza Immunization Summit, 2016.). The momentum gained from 
the creation of the summit and the engagement of the multitude of summit partners along with 
the NVPO’s 2010 NVP and the publication of the updated NVAC recommendations in 2014, 
helped drive the development of a National Adult Immunization Plan (NAIP). Developed by the 
NVPO and released in early 2016, this plan is “intended to facilitate coordinated action by 
federal and nonfederal partners to protect public health and achieve optimal prevention of 
infectious diseases and their consequences through vaccination of adults” (U.S Department of 
Health and Human Services The National Vaccine Program Office, 2016, p. i). 
The ASH serves as the director of the NVPO and as such will also lead the 
implementation of the NAIP. The plan structure is founded on four key goals, each with specific 
strategies and objectives to reach those goals. The timeframe for the NAIP is aligned with the 
2020 targets for the existing national plans addressing vaccines, like Healthy People 2020 and 
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the NVP. Some of the goals can be standalone projects but others may be dependent upon the 
success of other goals as a stepping stone to success. The goals are: 
1. Strengthen the adult immunization infrastructure. 
2. Improve access to adult vaccines. 
3. Increase community demand for adult immunizations. 
4. Foster innovation in adult vaccine development and vaccination-related technologies  
(U.S. Department of Health and Human Services Vaccine Program Office, 2016b, p.i). 
The plan was developed after a comprehensive review of the current state of the research around 
barriers to adult immunization and consideration of the changing policies and practices in the 
healthcare delivery environment, such as ACA. These four goals share common themes with the 
five categories of recommendations that came out of the 2012 NVAC recommendations (HHS 
National Vaccine Advisory Committee, 2012). A formal environmental scan was conducted to 
review all adult immunization recommendations and reports issued between 2005 and 2015, 
many of which we have addressed here (U.S. Department of Health and Human Services 
National Vaccine Program Office, 2016a). The environmental scan also included stakeholder 
surveys and feedback. These stakeholders included various groups of partners like payers, 
employers, research organizations, healthcare providers, and professional associations. Focus 
groups were convened and subject matter experts were interviewed. Successful implementation 
of the plan will rely on contribution, coordination, and collaboration from a wide variety of 
private and public entities.       
The NAIP had included indicators and performance measures which will be tracked 
against goals established and outlined in the plan (Department of Health & Services National 
Vaccine Program Office, 2016). Because many national indicators are already in place, such as 
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the HP 2020 goals, care was given to aligning goals within NAIP to existing national plans (if 
existing immunization goals were identified in other national plans, they were not changed) 
(Department of Health & Services National Vaccine Program Office, 2016). Measuring progress 
is a great step forward, however given that there are no specific incentives or disincentives for 
patients, providers, and NAIP partners ensuring improvement will be largely dependent upon the 
successful collaboration of the public private partnership groups like the NAIIS, and IAC 
(Department of Health & Services National Vaccine Program Office, 2016 ).  
Adult Immunization Barriers  
 There are many reasons attributed to low vaccination rates among adults. Adult 
vaccines have not benefited from the robust infrastructure for delivery that exists for pediatric 
vaccinations. Pediatric vaccine delivery has many benefits including, routine patient visits 
(especially for infants), long standing vaccine financing programs beginning with federal 
funding for polio vaccination in 1955 (Centers for Disease Control and Prevention, 1999) and  
the Vaccines for Children (VFC) program which was created by the Omnibus Budget 
Reconciliation Act of 1993 and implemented in 1994 (Centers for Disease Control and 
Prevention, 2014). There is also greater public awareness of the needs and benefits of pediatric 
vaccination as well as state level policy requirements for many pediatric vaccinations to be 
completed prior to school entry (Cole & Swendiman, 2014). 
 The NAIP environmental scan included a stakeholder survey to identify current 
perceptions of barriers to adult immunizations (Department of Health & Services National 
Vaccine Program Office, 2016). Goals of the plan have been developed around addressing these 
specific barriers. Unlike pediatric vaccinations, administration of adult immunization is 
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complicated by many variables including varying age ranges for delivery of adult vaccines and 
variables such as different recommendations by age determined by a variety of risk factors. 
Adults also see a larger variety of care givers and many do not have a defined medical home 
which complicates coordination of care. Disjointed care delivery also impacts appropriate record 
keeping for adult immunization status.    
Identifying and tracking adult immunization status impacts appropriate delivery of 
vaccinations. Reducing missed opportunities to immunize adults each time they see a healthcare 
provider can significantly improve delivery of adult immunizations (National Vaccine Advisory 
committee, 2014). A key challenge is for the provider to have adequate patient immunization 
history at the site and time of patient care. In addition, many opportunities to vaccinate are 
missed because vaccination status is not routinely being evaluated at every physician visit or 
healthcare provider encounters (Hurley et al., 2014). Immunization Information Systems (IIS) 
also referred as “registries” are “confidential, computerized, population-based systems that 
collect and consolidate vaccination data from vaccination providers that can be used in designing 
and sustaining effective immunization strategies” (Frieden, Jaffe, Stephens, & Thacker, 2012, p. 
1005). As of 2012 the CDC reported most all states had an IIS with the exception of the District 
of Columbia (DC) and New Hampshire and only two states were not collecting adult 
immunization data as of 2012 (Connecticut and Rhode Island) (Frieden, Jaffe, Stephens, & 
Thacker, 2012, p. 1005, pp.4). IIS’s have been an important technological tool to maintain 
patient level immunization data. A limitation for adults’ inclusion in registries is that adults are 
just now migrated into the systems as they receive vaccines and prior vaccination histories for 
adults are not captured in the registries. The adoption of IIS reporting by other healthcare 
providers such as pharmacists has greatly assisted in the ability to communicate immunization 
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status of adults between various providers since adults are more likely to seek care from more 
than one provider (Frieden et al., 2012, p.1006, pp.3). In many cases use of IIS is a mandatory 
requirement for alternate providers.  
In 2010 the Community Preventive Services Task Force recommended the use of 
immunization information systems on the basis of “strong evidence of effectiveness in increasing 
vaccination rates” (The Community Preventive Services Task Force, 2010). Specifically the 
report outlined 5 capabilities provided by IIS’s that demonstrated effectiveness in improving 
immunization rates: (1) create or support effective interventions such as client reminder and 
recall systems, provider assessment and feedback, and provider reminders, (2) determine client 
vaccination status for decisions made by clinicians, health departments, and schools, (3) guide 
public health responses to outbreaks of vaccine-preventable disease, (4) inform assessments of 
vaccination coverage, missed vaccination opportunities, invalid dose administration, and 
disparities in vaccination coverage, and (5) facilitate vaccine management and accountability 
(The Community Preventive Services Task Force, 2010). 
An outstanding limitation of IIS’s is the fact that they are state based systems and do not 
have the capacity to share immunization data between states and technical limitations exist for 
ease of transfer of IIS data within and between health systems and providers. In 2012 in an effort 
to address appropriate use of IIS’s among all age groups the National Center for Immunization 
and Respiratory Diseases (NCIRD), a division of CDC introduced a strategic plan to facilitate 
that “real time, consolidated immunization data and services for all ages are available for 
authorized clinical, administrative, and public health users, and consumers, anytime and 
anywhere" (Centers for Disease Control and Prevention, 2015a). This project aims to maximize 
the use of health information technology through bi-directional information sharing between 
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providers and state immunization registry databases allowing patient immunization records to 
cross populate between the registries and electronic health record systems. This enhanced 
capacity will allow for greater provider access to patient immunization status in order to more 
efficiently identify patients who have not received all recommended vaccinations. 
Interoperability between immunization registries and healthcare providers as well as 
complimentary immunization providers such as pharmacy’s will greatly assist in the 
identification of patients in need of immunization and over time as the databases become more 
robust they can have great utility to identify coverage trends and provide other epidemiologic 
surveillance data. The inability for information to be shared between states has been a notable 
limitation, particularly in areas where people live close to state borders and may get care in more 
than one state. Presently there are some pilot programs being undertaken to test cross state 
capacities but due to multiple technical variability’s  it is not likely that this problem will be 
resolved any time soon (Centers for Disease Control and Prevention, 2015b).       
Non- economic factors associated with barriers to adult immunization include activities 
facilitated within the provider’s office. As noted by the NAIP survey, lack of awareness of the 
need for adult immunizations, lack of a strong recommendation from a healthcare provider, and 
limited application of technology to support patient identification, physician flags, and reminder 
recall systems are a subset of barriers in and of themselves. One could also argue that skepticism 
about safety and efficacy, lack of public knowledge about adult immunizations, and the role of 
media influences also have a place within the purview of the healthcare provider environment.    
Prior to the NAIP environmental scan, a multitude of studies had cited the importance of 
a strong provider recommendation as a key factor in improving adult immunizations rates 
(Hurley, Lindley, Harpaz, Stokley, & Daley, 2010; Bridges et al., 2015; Hurley et al., 2010). 
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Strength of provider recommendation along with same day delivery of vaccination has been 
demonstrated as a proven strategy to improve adult immunization rates (National Vaccine 
Advisory committee, 2014). Factors which affect the strength of provider recommendations 
range from the lack of awareness on the part of the provider to a significant number of providers 
who do not stock routinely recommended vaccines for adults. If a physician is not stocking 
vaccines, they are far less like to make recommendations or refer patients for ACIP 
recommended vaccines. Recent national recommendations including the 2014 NVAC report 
provides vaccine recommendation standards for all providers, including those who do and do not 
stock and or administer vaccines (National Vaccine Advisory Committee, 2014).   
     Racial and ethnic disparities continue to persist in adult immunization coverage 
statistics. The 2015 NHIS found that whites adults generally had higher immunization rates 
compared to other groups and rates were generally higher among those who reported having a 
regular place where they received their healthcare services (Williams et al., 2017). The gap in 
racial and ethnic disparities for children has been narrowing and in aggregate significant 
disparities do not exist, possible factors contributing to better coverage among racial and ethnic 
groups for children are increased awareness of pediatric vaccines, better coverage programs for 
those who are un-insured or under-insured (VFC program), and school entry requirements (P. Lu 
et al., 2015). Identifying and removing barriers that specifically impact racial and ethnic 
minorities can help improve immunization rates. For example from 2007 to 2012 when the 
availability of influenza vaccination in multiple settings was increased, gaps in influenza 
vaccination coverage reduced slightly in non-Hispanic blacks and Asians compared to non-
Hispanic whites (Lu et al., 2015, p. S423). Lu et al., recommend additional assessment of racial 
and ethnic disparities beyond data collected from NHIS is needed. 
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Lack of insurance coverage is a well-documented barrier to adult immunization coverage 
(Lu, O’Halloran, & Williams, 2015; Williams et al., 2016). For example in 2015, Lu, 
O’Halloran, and Williams reported that pneumococcal coverage for at risk adults between 18-64 
years of age, for whom vaccination is routinely recommended, was 9.8% for uninsured 
compared to 23% for insured patients and influenza coverage rates were 14.4% versus 44.3% for 
uninsured versus insured (P.-J. Lu et al., 2015). In the post ACA era, understanding why such a 
large percentage of the population still does not have health insurance coverage for vaccination, 
which is covered at no out of pocket cost needs to be better understood. In addition 
immunization rates even among the insured are still exceptionally low. The ACA requirement 
for coverage of preventive care services including vaccinations was placed into effect starting 
with the first plan year after September of 2010, and allowed for “grandfathered” plans 
(determined as plan that was in effect as of March 2010) to be exempt unless changes were made 
to any portion of the plan (Koh & Sebelius, 2010; Rosenbaum, 2011). As of 2014, approximately 
26% of those with employer provided health insurance were still in “grandfathered” plans (The 
Henry J. Kaiser Family Foundation, 2014). Data from the most recent report from the Census 
Bureau and the U.S. Department of Commerce on health insurance coverage, shows that the rate 
of those uninsured decreased by 2.9% between 2013 and 2014 and that 66% of the population 
had private insurance comparted to 36.5% with some form of government insurance coverage 
(Smith & Medalia, 2015). Between 2013 and 2014 health insurance coverage among those 19 to 
64 years of age increased 4.2% (Smith & Medalia, 2015 p.8). Due to eligibility for Medicare, 
rates of insurance coverage for individuals over age 65 vary very little from year to year (Smith 
& Medalia, 2015, p. 7-8). Coverage for those under public plans such as Medicare and Medicaid 
has experienced less direct benefits from the ACA. Provision for immunization coverage under 
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Medicare and Medicaid vary and moreover while Medicare immunization coverage and benefit 
design is established at the federal level, coverage for immunizations under Medicaid is 
determined at the state level (Rosenbaum et al., 2003). 
U.S. Vaccine Policy  
Authority for mandating vaccines resides within States rights. Under the Public Health 
Service Act, HHS has the authority to “prevent the introduction, transmission, or spread of 
communicable diseases from foreign countries to the states or from state to state” (Cole & 
Swendiman, 2014, p.1). This includes authority to establish quarantine and isolation in order to 
halt the spread of communicable diseases however this does not include authority to mandate 
routine vaccination within states. Currently the only mandatory vaccination laws in the United 
States are those established for childhood school entry. As a result of measles outbreaks in 
schools in the 1960’s and 1970’s (measles virus can be aerosolized and therefore easily 
transmitted in the air where it can remain for up to 2 hours)(Centers for Disease Control and 
Prevention, 2017) adoption of school entry requirements were established to reduce transmission 
of measles and subsequently other communicable diseases among children (Cole & Swendiman, 
2014). In the decades following mandatory school entry immunization requirements have been 
expanded to include a variety of immunizations for diseases which are highly communicable like 
measles and some which are not such as HPV. Currently all states, including the District of 
Columbia have laws requiring immunizations for school entry however states vary widely with 
regard to what vaccines are required and at what age they must be received (Cole & Swendiman, 
2014). With regard to states mandating adult immunizations, a handful of states have 
requirements for immunization of healthcare workers for certain highly communicable diseases 
such as measles, mumps, rubella, and influenza, and some states require hepatitis B and 
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meningococcal vaccination for college students but these requirements often have very liberal 
“opt-out” provisions (Cole & Swendiman, 2014). Federal compulsory vaccinations have been 
established by the Secretary of HHS for immigrants of all ages entering the United States and 
these generally include all vaccines routinely recommended by the ACIP, with the exception of 
human papillomavirus and herpes zoster vaccination (Cole & Swendiman, 2014). 
Immunizations and the Affordable Care Act (ACA)  
The ACA of 2010 has the potential to be the most significant driver of improving adult 
immunization rates seen to date. One of the major goals of ACA is to increase health insurance 
and subsequently access to care for virtually all Americans. In addition to increasing access to 
care the ACA also requires coverage of certain preventive health services under the ten essential 
health benefits provision of the act, including all ACIP routinely recommended vaccines which 
must be covered with no out of pocket costs and no deductible (The Henry J. Kaiser Family 
Foundation, 2014). Challenges with delivery of adult immunizations have long been centered on 
issues of payment coverage. Without a federally subsidized program like the VFC program there 
was not a mechanism to provide coverage for adult immunizations to those who lacked private 
insurance and there were no requirements (or incentives) for private insurance payers to cover 
routine adult vaccinations. ACA was a huge game changer for immunization coverage at a 
population level however the Kaiser Family Foundation reports that public awareness of the 
preventive service requirement is very low, as of 2014 less than half the population (43%) was 
aware of the no out of pocket cost provision (The Henry J. Kaiser Family Foundation, 2014). 
The requirement for preventive services coverage through ACA applies to all private insurance 
plans, with the exception of plans that met a “grandfathered” status (Henry J. Kaiser Family 
Foundation, 2015).  
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While the ACA significantly improved access to vaccines for millions of patients by 
removing the financial barrier of patient out of pocket costs, the behemoth legislation contained 
no provision for or discussion of financial barriers at the provider level regarding stocking and 
inventory management and cost of administering vaccines (Department of Health & Services 
National Vaccine Program Office, 2016, p. 24). In an acknowledgement of the significance of 
the financial barriers associated with providers acquiring, stocking, and administering vaccines, 
the NAIP includes a specific objective dedicated to this topic (Department of Health & Services 
National Vaccine Program Office, 2016, p. 24). Goal 2 of the NAIP is to “Improve Access to 
Adult Vaccines”, and there are four objectives for this goal and objective 2.2 is to “Assess and 
improve understanding of providers’ financial barriers to delivering vaccinations, including 
stocking and administering vaccines (Department of Health & Services National Vaccine 
Program Office, 2016, p. 24). 
Population Health   
Nash, Reifsnyder, Fabius, and Pracilio define the primary components of the population 
health as; integrated health promotion and chronic illness disease management in the context of 
determinants of health (Nash, David, Reifsnyder, Fabius, & Pracilio, Valerie, 2011, p.7.). The 
term “population health” has recently been popularized as a staple in the healthcare lexicon, and 
it has been widely associated with and even attributed to the “Triple Aim”, established by 
Donald Berwick and others at the Institute of Healthcare Improvement (IHI) in 2007 (Institute 
for Healthcare Improvement (IHI), 2016). In 2003 Kindig and Stoddart published a 
comprehensive articulation of the term “population health” (D. Kindig & Stoddart, 2003). In 
their article titled “What is Population Health?” published in the American Journal of Public 
Health in 2003, Kindig and Stoddart asserted that population health was a relatively new term 
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which had not yet been precisely defined and therefore proposed their own definition as; “the 
health outcomes of a group of individuals, including the distribution of such outcomes within the 
group,” and they further argued “that the field of population health includes health outcomes, 
patterns of health determinants, and policies and interventions that link these two” (2003, p. 
380). In the time since that publication there has been much discussion and debate about how to 
define population health and how it is different than public health. In 2007 questions still 
remained as to whether population health was a concept of health or a field of study of health 
determinants and if population health and public health were the same or different (Kindig, 2007, 
p. 139). There are a vast number of definitions of public health. Here are just two examples 
selected from well-respected U.S. national health organizations; the CDC and the IOM: 
Public health is the science of protecting and improving the health of families and 
communities through promotion of healthy lifestyles, research for disease and injury 
prevention and detection and control of infectious diseases. Overall, public health is 
concerned with protecting the health of entire populations. These populations can be as 
small as a local neighborhood, or as big as an entire country or region of the world (CDC 
Foundation, n.d.). 
“What we as a society do collectively to assure the conditions in which people can be 
healthy” (IOM, 1988:1). Although government bears special legal responsibility, this and 
similar definitions extend to more than just the activities of government, broadly referring 
to the efforts, science, art, and approaches used by all sectors of society (public, private, 
and civil society) to assure, maintain, protect, promote and improve the health of the 
people (IOM, 1988; Last, 1995; Petersen and Lupton, 1996; Acheson, 1998; ASPH, 
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1999;Kass, 2001; Turnock, 2001).” (The Future of the Public’s Health in the 21st 
Century, 2003). 
As you can see from the 2003 IOM definition, many researchers and academicians have weighed 
in on defining public health. Both of these definitions are well aligned with traditional thinking 
around the role of public health however they both fail to addresses quantifiable metrics and 
activities which can assess outcomes which can then be used to achieve the goal of “protecting 
and improving the health families and communities”. Kindig suggests that distinguishing the 
difference between public health and population health essentially comes down to the more 
specific intention of population health which is to focus on the measurement of healthcare 
outcomes (2007, p. 143). I agree with this view and furthermore I would submit that not 
intentionally and thoughtfully measuring the results of our health improvement efforts so we can 
most efficiently deploy our resources to achieve the most optimal health improvements is 
contradictory to any definition of public health.  
 In Kindig’ s 2007 article on population health terminology, his stated goal is to provide a 
“concise compilation of terms and concepts useful to public and private policy makers, students 
and scholars from other fields” (2007, p.140). In this paper he provides updated comprehensive 
definitions of population health terms which provide additional granularity to the distinction 
between public health and population health. 
 Population health: (1) A conceptual framework for thinking about why some 
populations are healthier than others, as well as the policy development, research agenda, 
and resource allocation that flow from it (Young 1998). (2) The health outcomes of a 
group of individuals, including the distribution of such outcomes within the group 
  
149 
 
(Kindig and Stoddart 2003). (3) The health of a population as measured by health status 
indicators and is influenced by social, economic, and physical environments; personal 
health practices; individual capacity and coping skills; human biology; early childhood 
development; and health services (Dunn and Hayes 1999), (Kindig, 2007, p. 145).  
Public health: (1) Activities that a society undertakes to assure the conditions in which 
people can be healthy. These include organized community efforts to prevent, identify, 
and counter threats to the health of the public (Turnock 2004). (2) What we do as a 
society collectively to assure conditions in which people can be healthy (IOM 1988) 
(Kindig, 2007, p. 146).  
In these updated more comprehensive definitions the major distinction between them continues 
to be the population health emphasis on health outcomes, indicators (for individuals and groups), 
distribution of outcomes, and the influencers that drive those outcomes, whereas the public 
health definition continues to emphasize the role of “assuring” a societal approach to engaging in 
activities related to health. I most prefer the population health definition by Dunn and Hayes as it 
provides for the recognition and inclusion of  a variety of  “determinants” which can then be 
measured and evaluated in order to identify the most effective interventions to advance the 
population health continuum (Dunn & Hayes, 1999). 
 In 2015 Kindig authored a Health Affairs blog in which he posted that the term 
population health required additional evolution due to its close association with the Triple Aim 
and its wide use by health organizations to describe patient clinical outcomes both of which in 
his view have created conflicting understandings of the term (2015). Kindig argued that there is 
now a need for multiple definitions, primarily to address new terms which are used to “describe 
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activities limited to clinical populations and a narrower set of health outcome determinants” 
(2015). Because “population health” has become a rather generic term, straying from his 
intended purpose which was to establish greater focus on the role of non-clinical factors such as 
education and economics, Kindig proposes the use of the term “population health management 
(PHM)” or “population medicine”, to be used when referring to patient populations and then the 
original term “population health” could be used to represent geographic populations. Other 
suggestions included replacing the term population health with “total population health” (D. A. 
Kindig, 2015b). Ultimately the IOM roundtable on Population Health Improvement elected to 
maintain the term “population health” while acknowledging its intended objective to align with 
geographical outcomes and not clinical populations. Kindig acknowledges that to some this 
discussion may appear to be just semantics (2015) but my own research has lead me to agree 
with the need to more clearly define the terms. There are too many concepts now being included 
in “population health” terminology and the critical intended distinction in adopting the term 
population health, as put forth by Kindig and Stoddard (2003), was to focus on outcomes and 
how determinants (specifically economic and social) factored into those outcomes. 
 The most simplistic distinction between population health and public health is that 
population health refers to specific measurable health outcomes and population health defines 
more of the approaches we use to provide health to the nation’s population. 
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Appendix B: 2017 Adult Immunization Schedule 
 
 
  
152 
 
  
153 
 
  
154 
 
 
 
 
 
 
 
 
 
  
155 
 
 
 
 
 
APPENDIX C: PERMISSION TO USE MULTILEVEL INFLUENCES on SUCCESSFUL 
IMPLEMENTATION FIGURE 
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APPENDIX D: PERMISSION TO USE NATIONAL ADULT IMMUNIZATION PLAN 
FIGURES AND TABLES 
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APPENDIX E: PERMISSION TO USE 2017 ADULT IMMUNIZATION SCHEDULE 
 
 
